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ABSTRACT
Juglone, a naphthoquinone found in Juglandaceae family, which includes black walnut,
European walnut, and butter nut possess various biological activities. The anti-cancer properties
of juglone has been reported; however, the effect of juglone in pancreatic cancer (PC) has not been
elucidated yet. PC is an aggressive lethal, highly metastatic disease associated with poor prognosis
and high mortality rate. PC is usually diagnosed in advanced stage and chemotherapy is provided
as a first line of treatment. The de novo chemoresistance that develops with chemotherapeutic
treatment creates a critical need for identification of novel therapeutic agents for effectively
targeting the disease.
The effects of juglone on PC cell proliferation, level of reactive oxygen species (ROS)
production, and expression of various oncogenic signal transduction molecules in MIA Paca-2,
pancreatic carcinoma cells were investigated. The major findings indicate that treatment with
juglone dose dependently suppressed the in vitro proliferation and induced cell death of rapidly
dividing human PC cells with an IC50 value of 5 μM at 24 h. Long-term colonies forming ability
of PC cells was also significantly inhibited. The molecular mechanisms behind juglone-induced
apoptosis of PC cells indicated activation of caspase-3, cleavage of PARP, upregulation of Bax,
down regulation of Akt, ERK, HER-2, Cox-2, and Bcl-2 and very high production of ROS leading
to chromatin condensation, DNA damage and cell death. Changes in morphological features of
cell treated with juglone were obtained by confocal microscopy using Hoechst staining, which
specified apoptotic features in treated cells. The results also revealed the anti-angiogenic and antimetastatic potential of juglone. PC cell migration and invasion was significantly reduced with
juglone treatment and the potential of endothelial cells to form tubes was also limited when treated
with juglone. Key angiogenic regulators such as HIF-1α and VEGF were also downregulated with
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juglone treatment. Taken together, our data suggest that of ROS-inducing agent juglone could
provide a novel therapeutic approach for PC treatment.
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CHAPTER 1. REVIEW OF LITERATURE
1.1. Natural Phenolic Compounds
Medicinal properties of natural herbs and botanicals provide a major contribution as a
source for new pharmaceutical discoveries [1, 2]. Plant derived components are gaining attention
for promoting good health and defined as functional foods and nutraceuticals. The phenolic content
of plants has been categorized into more than 20 different groups.
Natural products comprise a significant percentage of anti-cancer drugs that are currently
used for treatment. Globally, more than fifty percent of drugs that have been used in cancer
treatment from 1940 to 2006 were reported to be either natural products or their derivatives [2, 3].
The National Cancer Institute of the United States began screening plant extract for anti-tumor
activities in the 1960s [5] and since significant progress has been made in the pharmacology of
natural products. Drugs made from natural products include paclitaxel, docetaxel and others [6].
1.2. Secondary Metabolites from Plants
Secondary metabolites (SM) are the low molecular weight non-essential components of the
plant and are produced as a defense mechanism by plants against their competitors, insects,
herbivores, microbial pathogens or to attract insects for pollination. Other abiotic factors that
induce production of SM by plants include UV exposure [7]. SM play an integral role in a plant
life cycle for its survival and reproduction. The pharmacological values of many SM have been
recognized. SM represent a huge variety and diversity; a single plant can produce a complex
mixture of SM. Thousands of structures of SM have been identified and can be divided into two
different groups; nitrogen containing compounds and compounds with no nitrogen, which are
listed in Table 1.1.
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Table 1.1: Number of Structurally known Secondary Metabolites [8, 9]
Secondary Metabolite (SM)
Nitrogen
Containing SM

Number of Structures

Amines

100

Alkaloids

21000

Non protein amino acids

700

Cyanogenic glucosides

60

Glucosinolates

100

Alkamides

150

Lectins, peptides

2000

SM containing Monoterpenes
no nitrogen
Sesquiterpenes

2500
5000

Diterpenes

2500

Triterpenes

5000

Tetraterpenes

500

Polyketides, quinones

750

Polyacetylenes, fatty acids, waxes

1500

Flavonoids

4000

Phenylpropanoids, lignin , coumarins, lignans

2000

1.2.1. Quinones
Quinones are secondary metabolites derived from plants or microorganisms. Quinones are
a class of organic compound usually derived from aromatic compounds such as benzene or
naphthalene. They are found especially in the plant kingdom in higher plants, fungi and bacteria
and in the animal kingdom in arthropods and echinoderms. They range from pale yellow to black
in color and are used in the food industry as food colorants. They are also used as dyeing agents
and are valued for their therapeutic benefits as well. Diet, drugs and environment are some of the
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medium for exposure of quinones to human. There are different types of quinones with remarkable
therapeutic applications. Based on the number of fused benzene rings in the structural skeleton,
they have been divided mainly into four different groups; benzoquinone, naphthoquinone,
phenanthrenequinone, and anthraquinone. Examples of these quinones and their basic structure
are listed in Table 1.2.
Out of different groups of quinones, anthraquinones are the largest group of naturally
occurring quinones. The name of quinone-based compounds are usually derived from their parent
aromatic compound [10]. For instance, naphthoquinones are derived from naphthalene,
benzoquinones are derived from benzene, and anthraquinones from anthracene. Quinones are
abundantly found in nature.
More than 1200 types of quinones have been reported in literature [11]. They primarily
function as electron carriers in plants and are very well known for their cytotoxicity by radical
formation though electron transport where the quinone ring is of major importance [12]. Other
mechanisms that have been associated with quinone-induced cytotoxicity are its ability to form
cell adducts, intercalate DNA, cause alkylation, and inhibit proteins and enzymes such as
topoisomerases [12].
1.2.2. Quinones for Anti-Cancer Therapy
Quinones make one of the largest group of compounds used against cancer [14]. Some of
the various drugs against cancer that have been approved and those going through clinical trials
are quinone-based compounds such as actinomycin D, anthracylines, daunorubicin, menadione,
mitomycin C, mitoxantrones, saintopin, and trenimon [15, 16]. This validates the importance of
naturally occurring quinones for drug development in cancer research.
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Table 1.2: Examples and basic structures of some quinone [9, 13]
Types of Quinones

Examples

Basic Structure

Anthraquinones

Rhein, emodin, aloe-emodin

Phenanthraquinones

Denbinonbin, bulbophyllanthrone

Benzoquinones

Embelin, embelinol, thymoquinone

Naphthoquinones

Juglone,
Plumbagin,
Lawsone, Menaquinones

Shikonin,

1.2.3. General Mechanisms behind Quinone-based Toxicity
Bio-reductive activation of quinones and generation of reactive oxygen species are the
major events behind the biological activity of quinones [10]. Quinones can undergo reduction via
2 different pathways; a. one electron reduction b. two electrons reduction as shown in Figure 1.1.
Semiquinones are formed via one electron reduction of quinones, which is catalyzed by enzymes
like NADPH-cytochrome P450 reductase, resulting in generation of O2- and H2O2. Hydroquinones
are usually formed by 2 electron pathway, and this reaction is catalyzed by NADPH:quinone
oxidoreductase 1 (NQO1) or DT-diaphorase. Quinones are electrophilic in nature and this
4

promotes the reaction with cellular components especially with macromolecules containing thiol
groups. This electrophilic reaction provides quinone with a cytotoxic property [11].

Figure 1.1. Reduction of quinone
1.3. Juglone (5-hydroxy- 1, 4- naphthoquinone)
Naphthoquinones are found in almost 20 families of higher plants like Ebenaceae,
Droseraceae,

Balsaminaceae,

Juglandaceae,

Plumbagnaceae

and

others.

Juglone,

a

naphthoquinone is a major component found in the nuts, hulls, leaves, roots, and bark of plants in
Juglandaceae family, which includes black walnut (Juglans nigra L.), European walnut (Juglans
regia L.), butter nut (Juglans cinerea) and others [17]. Plants in the Juglandaceae family contain
about 50 species in 8 genera and usually grow in the northern temperate and subtropical climate
zone [18]. These plants are widely distributed in southern Europe, northern Africa, eastern Asia,
the USA, and western South America.
The amount of juglone in plants varies depending on the source and varieties. The
molecular weight of juglone is 174.14 and its melting point is 155oC. It is soluble in alcohol,
acetone, acetic acid, chloroform, benzene, DMSO and is slightly soluble in hot water [18]. The
structure of juglone is shown in Figure 1.2. In a sample of 1121 different plants, the amount of
juglone ranged from 13 to 1500 mg/100g dry weight [19]. Normal-phase liquid chromatography
is a simple and rapid method used for the determination of juglone with a reported retention time
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of 4.27 min [18]. Juglone was used in ancient medicine for ringworm, fungal, bacterial and viral
infections, and for its allelopathic activity in plants [20].

Figure 1.2. Structure of juglone
1.3.1. Biosynthesis of Juglone
Juglone is biosynthesized in plants from the ortho-succinylbenzoic acid (OSB) of the
shikimic acid pathway [21]. The shikimic acid pathway is the major route for the formation of
secondary metabolites in higher plants [22]. This pathway does not occur in animals, but only in
higher plants and microbes. Aromatic compounds and some of the essential amino acids are
formed via this pathway. An intermediate that is reported to be involved in the biosynthesis of
juglone is 1, 4 naphthoquinone and its decarboxylation and hydroxylation results in the formation
of juglone as illustrated in Figure 1.3. Juglone is present in both free as well as glucosidic form in
plants. The glucosidic form of juglone (1, 5-dihydroxy-4-naftalenyl-β-D-glucopyranoside) is
usually decomposed by the enzyme hydrojuglone-β-D-glucopyranosid-β-glucosidase to juglone
[23].
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Figure 1.3. Biosynthesis of juglone [24]
1.3.2. Chemo-preventive Activity of Juglone
There are very limited studies on the anti-cancer activities of juglone. However, a very
closely related compound plumbagin (2-methoxy -5-hydroxy,1,4 naphthoquinone), an analogue of
juglone has been extensively investigated for its anti-cancer properties. Plumabgin and juglone at
200 ppm reduced the occurrence of multiple intestinal tumors in azoxymethane (carcinogen)induced colon cancer in rats [25]. Both plumbagin and juglone had significant effect against tumor
initiation and multiplication, but the underlined mechanism was not detailed.
Juglone dose-dependently inhibits melanoma cells viability. The IC50 for juglone in B16F1
melanoma cells at 1, 24 and 48 h was found to be 9.9 µM, 7.46 µM and 6.92 µM respectively [17].
Very high intracellular production of ROS was linked to the mode of action of juglone mediated
apoptosis in melanoma cells. Peptidyl prolyl isomerase Pin1 activity is very high in various
cancers, which is induced by oncongenes such as Ras and Neu. Pin 1 is also associated with
regulation of cyclin D1. Juglone has been reported to inhibit Pin1 activity [26]. Expression of
oncogenic Ras is highly elevated in pancreatic cancer and juglone being an inhibitor of Pin1, which
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is a downstream molecule of oncogenic Ras signaling pathway [27], juglone seems to be a
promising compound against pancreatic cancer.
Juglone has been reported to be the substrate for NADPH-cytochrome P450 reductase and
DT-diaphorase [11], which means it can either be reduced by one electron or 2 two electron
pathways.
1.4. Thymoquinone (TQ)
TQ (2-isopropyl-5-methyl-benzoquinone) is the principal bioactive component of the
volatile oil of Nigella sativa (black seed). The structure of TQ is shown in Figure 1.4. The content
of TQ in black seed oil as analyzed by HPLC has been reported to be 27.8% [28]. Black seed oil
has been extensively used in traditional medicine in the Mediterranean region and Asian continent
[29] for its anti-inflammatory [30], anti-diabetic [31], and anti-microbial [32] properties.

Figure 1.4. Structure of thymoquinone
The compound was isolated from black seed 50 years ago and has been studied ever since
[1]. Various studies have been carried out to understand the effect and mechanism of TQ on
different types of cancer cells. TQ inhibits various cancer cells in-vitro and in vivo and has been
suggested to undergo clinical trials [33].The toxicity of TQ has proven to be very low in
experimental animal models. The LD50 in rats and mice models after intraperitoneal injection was
found to be 57.5 mg/kg and 104.7mg/kg whereas in oral administration the LD50 was 794.3 mg/kg
and 870.9 mg/kg, respectively [34].
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All different hallmarks of cancer has been found to be affected by TQ except “evasion of
immune system” [1]. As illustrated in Figure 1.5., generation of reactive oxygen species [35],
translocation of phosphatidylserine [33], chromatin condensation [36], inhibition of angiogenesis
[37], and control of invasion and metastasis [38] are some of the approaches by which TQ acts on
cancer cells. As TQ possesses so many desirable effects against cancer and has already been used
in many combinatorial therapies with chemotherapeutic agents, hormones or ionizing radiation [1,
39], combination of juglone and TQ was therefore designed in order to target the multipathophysiological processes in pancreatic cancer as discussed in Chapter 2.

Figure 1.5. Mode of action of TQ [1]
1.5. Hallmarks of Cancer
Hanahan and Weinberg in 2000 had summarized the key features of cancer cells in six
hallmarks [40], which are listed and discussed below. These six hallmarks of cancer are shared by
all types of cancer. The concept of the hallmarks has remained the same since the last decade, but
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in 2011 a few new features were added to the list namely including cancer cell metabolism and
evasion of immune-surveillance [41].
1. Self-sufficiency in growth signals
2. Abrogation of Growth Suppressors
3. Evasion of Apoptosis
4. Unlimited Replicative Potential
5. Induction of Angiogenesis
6. Activation of invasion and metastasis
7. Metabolism
8. Evasion of immune surveillance
1.5.1. Self-sufficiency in Growth Signals
Normal cells require reception of growth signals in order to proceed through cell division
and growth cycle, which helps them to maintain homeostasis in a cellular environment and ensures
formation of a normal tissue. In contrast to normal cells, tumor cells act independently to growth
signals and have deregulated mechanisms that disrupt the balance in cell numbers and results in
chronic proliferation of cancer cells. Various factors that contribute to reduced dependency of
cancer cells to growth factor signals have been identified. Cancer cells have the ability to generate
growth factors on their own and respond to it via expression of numerous growth factor receptors.
Alternatively, they can also signal surrounding normal cells to release growth factors required for
their growth [42]. Other differences that are seen in cancer cells include overexpression of growth
factor receptors that enables amplification of cancer cell signaling in response to a limited amount
of growth factor, and structural modification in growth factor receptors which causes cancer cell
signaling even in absence of growth factor ligand. Cancer cells containing these overexpressed
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growth receptors are found to contain somatic mutation that triggers hyper-activation of
downstream signaling cascades inside the cells such as activated Ras-Raf-MAPK (mitogenactivated protein kinase) pathway and phosphoinositide 3-kinase (PI3K)/Akt signal transduction
pathway which can be related to increased proliferation.
1.5.2. Abrogation of Growth Suppressor Signals
In order to maintain tissue homeostasis and cells senescence, normal cells exhibit antiproliferative mechanism by responding to anti-growth factors or growth inhibitors. These
inhibitors are either in solubilized or immobilized forms embedded in the extracellular matrix.
These inhibitors are recognized by the cell surface receptors. These receptors further induce
intracellular anti-growth signaling in cells resulting in their quiescent stage or differentiated stage
losing their ability to proliferate. In contrast, cancer cells resist anti-growth signals by disrupting
action of many tumor suppressor genes. These genes encode tumor suppressor proteins like RB
(retinoblastoma-associated) and TP53 (tumor protein p53) that play a major role in controlling
proliferation and cell cycle progression by activating senescence and apoptosis. However both of
these proteins are found to be defective in most of the cancers. Besides inhibiting tumor suppressor
proteins, tumor cells can also evade differentiation by overexpression of the oncoprotein c-Myc
[43].
1.5.3. Evasion of Apoptosis
Apoptosis is also called programmed cell death. It is derived from the Greek words
meaning “falling off” like leaves in autumn and was first coined by Kerr, Willie, and Currie in
1972 [44]. Physiological significance of apoptosis is to maintain a balance in cell population and
the process is very high during embryonic development, when the tissues are going through
sculpting and during aging [45]. Dysregulation of apoptotic process leads to various pathological
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conditions such as cancer, Alzheimer’s disease and Parkinson’s disease. Cancer cells acquire the
ability to resist apoptosis.
The apoptotic process includes upstream regulators and downstream effector components.
The regulators of apoptosis can either be extrinsic or intrinsic. The extrinsic regulation includes
different cell surface death ligand receptors including the Fas ligand and TNF receptor. The
intrinsic regulation monitors condition of the cells and activates apoptosis in detection of
abnormalities within the cells such as DNA damage, hypoxia or survival factor insufficiency.
These apoptotic signals converge in the induction of release of mitochondrial pro-apoptotic protein
cytochrome C whose release is regulated by the Bcl-2 family of proteins. Both kinds of regulation
eventually initiate the caspase cascade and converge to the activation of common executioner
protease, caspase-3 responsible for the execution of apoptosis.
In case of cancer, the process of apoptosis is unregulated. Tumor cells evade apoptosis
through a variety of mechanisms. Some of the mechanisms responsible for evasion of apoptosis
include mutation of tumor suppressor gene p53, overexpression of anti-apoptotic regulators like
Bcl-2 and c-myc, and downregulation of pro-apoptotic factors like Bax and cytochrome-C. The
PI3K/Akt pathway, which is responsible for transmission of anti-apoptotic cell survival signals is
also activated in human tumors and this alteration also enables the evasion of apoptosis [46].
Apoptosis is triggered in cancer cells as a vital anti-cancer therapeutic approach. The signaling
circuitry regulating apoptosis is further discussed in details in the following sections.
1.5.3.1. Cellular Changes during Apoptosis
Various morphological and biochemical changes occur in cells undergoing apoptosis.
Rounding up of the cells, chromatin condensation or pyknosis followed by nuclear fragmentation
or karyorrhexis, membrane blebbing, modification in structures of cyto-organelles, and loss of
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membrane integrity are some of the physical changes that are observed during apoptosis [4].
Apoptotic cells also go through numerous biochemical changes; activation of caspases,
degradation of DNA, and changes in plasma membrane like, externalization of phosphatidylserine
(PS) molecules. Expression of PS on the outer membrane of dead cells allows it to be recognized
by the macrophages and hence phagocytosis occurs. The process of dead cells undergoing
phagocytosis is just as important because if not the apoptotic bodies can induce neighboring cells
to induce production of pro-inflammatory cytokines that could have deleterious effect.
1.5.3.2. Mechanism of Apoptosis
Understanding the mechanism of apoptosis is very important with regard to drug
development. Schematic diagram of extrinsic and intrinsic pathway of apoptosis is shown in Figure
1.6. Caspases (Cysteine-dependent aspartate-specific proteases) play a major role in initiating and
executing apoptosis. They are usually present as inactive proenzyme and when activated initiates
activation of other caspases leading to a cascade of caspase activation. Activated caspases lead to
cleavage or change in many structural proteins, nuclear proteins or enzymes eventually causing
cell death. There are 12 different types of caspases found in human cells and only seven types of
caspases are involved with apoptosis. Caspases involved in apoptosis are divided as initiators (-2,
-8, -9, -10) and executioners (caspase -3, -6, and -7) [45]. Caspases are proteolytic in nature and
function through two major pathways as discussed below. Both of these pathways (extrinsic and
intrinsic) eventually lead to the execution of apoptosis.
1.5.3.2.1. Extrinsic Pathway: It is also referred to as the death receptor pathway which
starts with binding of death ligands to the transmembrane death receptors that belong to the tumor
necrosis factor (TNF) receptor gene superfamily [47]. These receptors have a cysteine rich
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extracellular domain and a cytoplasmic death domain. The death domain transmits intracellular
signals from the cell surface and initiates a series of events [48].

Figure 1.6. Extrinsic and intrinsic pathways of apoptosis [4]
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TNF receptors and FasL receptors are some of the receptors that receive the death signals
from their respective ligands, TNF and Fas [49]. Binding of the ligands to the receptor causes
recruitment of adapter proteins in the binding site of intracellular death domain of the receptor
forming the Death Inducing Signal Complex (DISC) [50]. TNF receptor-associated death domain
(TRADD) and Fas-associated death domain (FADD) are the adapter proteins for TNF receptor and
Fas receptor. DISC then activates pro-caspase 8. Activated pro-caspase 8 is the initiator caspase
and triggers the execution of apoptosis. FLICE (FADD-like IL-1β-converting enzyme)-inhibitory
protein (c-FLIP) and Toso are some of the inhibitor proteins of death receptor mediated apoptosis
[45].
1.5.3.2.2. Intrinsic Pathway: As the name suggests, this pathway begins from the
mitochondria within the cell. Stimuli like oxidative stress, hypoxia, toxins, radiation, and free
radicals trigger high mitochondrial permeability, loss of mitochondrial potential, which results in
opening of pores in mitochondria with release of pro-apoptotic proteins from the inner membrane
of mitochondria to the cytosol of cells. There are typically 2 groups of pro-apoptotic proteins
released in this manner. The first group consists of cytochrome C, second mitochondria derived
activator of caspase (Smac), direct inhibitors of apoptosis (IAP) binding protein with low pI
(DIABLO), and high temperature requirement protein A (HtrA2)/Omi and these proteins activate
the caspases. Cytochrome C acts by forming an apoptosome complex by binding with Apaf-1 and
pro-caspase 9 and the apoptosome complex activates the initiator caspase, caspase-9.
Smac/DIABLO and HtrA2/omi proteins bind to IAP, and promotes apoptosis by preventing it from
binding with caspase-9 or -3. The other group of proteins released from the mitochondria are
endonuclease G, Caspase-activated DNAse (CAD) and Apoptosis-inducing Factor (AIF). AIF and
endonuclease G function get translocated to the nucleus and cause DNA fragmentation and work
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in a caspase-independent mechanism whereas CAD after being translocated to nucleus has to be
first cleaved by caspase-3 in order to create distinct DNA fragmentation and chromatin
condensation.
The Bcl-2 family of proteins are accountable for the regulation of mitochondrial
permeability in this specific pathway. The major groups of proteins within Bcl-2 family can be
classified into pro-apoptotic and anti-apoptotic proteins. Anti-apoptotic proteins such as Bcl-2,
Bcl-x, Bcl-XL, Bcl-w, BAG play their role by blocking the mitochondrial release of cytochrome
C whereas the pro-apoptotic proteins such as Bcl-10, Bax, Bak, Bid, Bad, Bim, Bik and Blk
promote the release of cytochrome C.
1.5.3.2.3. The common Execution Pathway: Both the extrinsic and the intrinsic apoptotic
pathways converge to the common execution pathway, which is considered to be the final step of
apoptosis. Executioner caspases (caspase-3, -6, -7) are activated in this phase and stimulate the
activity of various endonucleases and proteases to degrade the nuclear material and cytoskeletal
proteins. Some of the substrates that are cleaved by executioner caspases are DNA repair proteins,
PARP (poly ADP ribose polymerase), cytokeratins and nuclear mitotic apparatus protein 1
(NuMA). These cumulative action of caspases and endonucleases causes the morphological and
biochemical changes seen in cells undergoing apoptosis. Once the cells undergo apoptosis the next
immediate step is the phagocytosis of the cellular components.
1.5.4. Unlimited Replicative Potential
Cancer cells acquire the property of unlimited replicative potential that results in
macroscopic tumors. Normal cells can only go through limited cell divisions. Senescence and crisis
restrict uncontrolled proliferation of normal cell. Senescence is an irreversible state where the cells
enter into a viable but non-proliferative stage and cells escaping senescence enter crisis stage which
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refers to cell death. There are rare occasions where cells from population of crisis escape and
achieve unlimited replicative potential termed as immortalization.
Telomeres are the TTAGGG sequences of DNA that are present at the ends of the
chromosomes and function to protect the chromosomal ends. In normal cells, with each cell
division, the length of telomeres shortens and eventually a limit is reached where the cells are
directed to arrest or senescence. The natural process of telomere shortening in normal cells with
each cell division leads consequently to a point where the cells lose their protective function and
senescence or apoptosis is triggered. This process is evaded by cancer cells with activation and up
regulation of telomerase, a DNA polymerase enzyme that adds telomere segments in the end of
the chromosome. The activity of telomerase is almost lacking in non-immortalized cells and found
significantly higher in malignant cancer cells, which helps cancer cells resist the induction of
senescence or crisis/apoptosis. Therefore, suppression of the enzyme telomerase in cancer cells
leads to telomere shortening and to activation of barriers to proliferation namely, senescence or
apoptosis.
1.5.5. Induction of Angiogenesis
Tumor cells need a supply of nutrients and oxygen and also require a system to evacuate
metabolic waste and carbon dioxide like normal cells do. These needs of tumor cells are met by
the process of neo-vascularization or angiogenesis. Normally, angiogenesis is very active only in
few cases during embryogenesis such as wound healing and female reproductive cycling, and
remains quiescent most of the time. A tumor cannot grow in size beyond 1-2 mm until it is supplied
with nutrients and oxygen. In case of tumor progression, the “angiogenic switch” is always turned
on which refers to a state where the balance of pro-angiogenic and anti-angiogenic factors is
disrupted and more inclined towards the pro-angiogenic factors such as vascular endothelial
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growth factors [51]. This process of angiogenic switch causes activation of normal quiescent blood
vasculature to form new blood vessels for growth of tumors which eventually leads to formation
of malignant tumors [51].
The angiogeneic switch in tumors are regulated by pro-angiogenic growth factors like
vascular endothelial growth factor (VEGF) or inhibitors like thrombospondin-1 (TSP-1). In some
tumors, oncogenes such as Ras and Myc are known to upregulate expression of pro-angiogenic
growth factors. Tumor-associated blood vessels formed by chronic activation of angiogenesis are
usually irregular with enormous sprouting of capillaries, distorted with enlarged vessels, and
contains inconsistent blood flow and leakiness [52]. Traditionally, tumor angiogenesis used to be
considered important only after the formation of macroscopic tumors, but recent data of
histological analyses of premalignant and non-invasive lesions have shown induction of
angiogenesis in early steps of tumor growth [53] both in animal and human models, making
angiogenesis a basic hallmark of cancer.
1.5.6. Activation of Invasion and Metastasis
Metastasis is a process where neoplastic cells disseminate, invade adjacent tissues and
grow at a site distant from the site of origin as depicted in Figure 1.7. [54]. It is the cause for more
than 90% of cancer related deaths. The process of invasion and metastasis is a multi-step process
and referred as the invasion-metastasis cascade. It consists of a series of the following steps [55]:
i. Infiltration of cancer cells to adjacent tissue (local invasion)
ii. Intravastation (migration of cancer cells into blood vessels)
iii. Transit of cancer cells through lymphatic and hematogenous systems
iv. Extravastation (movement of cancer cells from vessels to distant tissues)
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v. Formation of micro-metastases
vi. Growth of micro-metastatic tumor to macroscopic tumors also called (colonization)

Figure 1.7. Progression of cancer cells at primary and metastatic sites [56]
Tumor cells can invade the adjacent tissue in form of epithelial sheets, detached clusters,
single cells or amoeboid cell types [57]. Morphological and phenotypical changes that are seen in
metastasizing tumor cells are epithelial to mesenchymal transition (EMT), collective to amoeboid
transition (CAT) and mesenchymal to amoeboid transition (MAT) as illustrated in Figure 1.8.
EMT represents a crucial event in metastasis of cancer cells. This transformation of
epithelial cells provides the cells with capabilities to invade, to resist apoptosis and to disseminate.
EMT is regulated by a set of transcriptional factors like Snail, Slug, Twist, and Zeb1/2 [58].
Changes that are induced in cellular traits by these transcriptional factors are transformation from
a polygonal/epithelial to a spindly/fibroblastic morphology, expression of matrix degrading
enzymes, resistance to apoptosis, and loss of adherence and high motility which all contributes to
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invasion and metastasis of cells [59]. Reversal of EMT or mesenchymal to epithelial transition
(MET) also occurs in cancer cells after invading and metastasizing in order to re-colonize at a
secondary location and this feature helps cancer cells retain their histopathologic properties [60].
Besides EMT or mesenchymal invasion, the other two modes of invasion are collective
and amoeboid form of invasion. Cancer cells that undergo collective invasion maintain their intact
epithelial cell to cell contact and are infrequently metastatic. Unlike collective and mesenchymal
transition, the amoeboid kind of transition is protease-independent and instead of making a passage
in the extracellular matrix, involves sliding of cells through spaces in the extracellular matrix, and
is the fastest migratory phenotype [57].

Figure 1.8. Ongoing changes in invading cancer cells [54]. A. Sheets of cancer cells. B. Single
mesenchymal cell. C. Amoeboid cell movement. CAT, collective to amoeboid transition; EMT,
epithelial to mesenchymal transition; MAT, mesenchymal to amoeboid transition; MMP, matrix
metalloproteinase.
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1.5.7. Reprogrammed Energy Metabolism
Cancer cells require many nutrients and energy to fuel the ongoing metabolism in order to
maintain uncontrolled growth and proliferation. Changes in energy metabolism in cancer cells are
considered as a key regulator of tumorigenesis and has been added to the list of general hallmarks
of cancer [61].
For energy metabolism in normal cells in an aerobic condition pyruvate generated from
glycolysis is further converted to acetyl-CoA and CO2 via tricarboxylic acid (TCA) cycle and
oxidative phosphorylation with generation of 36 molecules of ATP per glucose molecule and only
in anaerobic condition pyruvate is converted to lactate. But in tumor cells, even in presence of
oxygen, most of the pyruvate generated through glycolysis is converted to lactate and only yields
2 ATPs. This phenomenon was first observed by Otto Warburg in the 1930s and is termed “aerobic
glycolysis” [61] and is illustrated in Figure 1.9. To compensate the lower yield of ATPs, glycolysis
is highly upregulated in cancer. Upregulation in glucose uptake and utilization via elevated
expression of glucose transporters like GLUT 1 and activity of glycolytic enzymes in cancer cells
are associated with higher expression of oncogenes like Ras and myc [62].
Glycolytic switch benefits cancer cells by utilization of intermediates formed during
glycolysis in the biosynthesis of macromolecules, lipids, nucleotides, amino acids and NADPH
[63]. For instance, metabolic intermediates like glucose-6-phosphate is used in the synthesis of
nucleic acids [64]. This formation and accumulation of biomass is eventually used in the promotion
of growth and proliferation of cancer cells. Besides that, lactate formed via aerobic glycolysis aids
invasion and metastasis as it lowers the pH of the surrounding environment, which activates
metalloproteases and helps in tumor progression by degradation of the extracellular matrix [65].
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Figure 1.9. Schematic representation of oxidative phosphorylation, anaerobic glycolysis and
aerobic glycolysis [66]
1.5.8. Evasion of Immune Surveillance
Immuno-evasion by cancer cells is another feature of cancer cells that has been added to
the existing list of hallmarks. The immune system of the body is responsible for the recognition
and elimination of cancer cells before they are established as a tumor mass. However, cancer cells
go through immune-editing and are found to escape detection and decrease the immunological
deleterious effect. Cancer cells disable the immune recognition system and evade immunesurveillance. For example, the action of cytotoxic T lymphocytes (CTLs) and natural killer (NK)
cells are restricted by release of immunosuppressive factors such as TGF-β [67].
The increased rate of cancer prognosis in colon and ovarian cancer patients with high CTLs
and NK cells depicts the importance of the immune system in anti-tumorigenesis. [68-70]. It has
also been shown that an immune-compromised organ recipient has a higher chance of donor
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derived cancer development. This suggests that the tumor free donor had a dormant state of cancer
cells well monitored by the active immune system [71].
1.6. Pancreatic Cancer
Pancreatic cancer (PC) is the fourth leading cause of cancer related death in the United
States. According to the American Cancer Society, in 2015 in the US, the estimated number of
new cases of PC was 48,960 and number of deaths was 40,560 [72]. PC is highly chemo-resistant
and the median survival rate due to PC is six months while the five years survival rate is less than
3-5% [73]. According to the Surveillance, Epidemiology and End Results registries, data on
treatment outcomes of patients from last three decades (1981-2010) have been analyzed and it has
been reported that there was a mere improvement in 1 year survival from 17% to 28.2% whereas
improvement in long term survival (≥ 5 years) remained low from 3.1 to 6.9% [74]. Several risk
factors have been identified for PC, which includes family history, smoking, alcohol, diet, diabetes
mellitus, obesity, and some genetic disorders [75].
The pancreas plays a major role in the digestion process and in maintenance of glucose
homeostasis. Exocrine and endocrine compartments are present in the pancreas for its
functionality. Exocrine compartment is primarily responsible for the production of digestive
enzymes and endocrine for hormones insulin and glucagon. Because of the variation of cell
composition in the pancreas, the types of tumors found in the pancreas are different. This study is
focused on pancreatic ductal adenocarcinoma or pancreatic cancer, which usually refers to
exocrine centered pancreatic tumor, for which there is a great need for therapies [76].
1.6.1. Risk Factors Associated with Pancreatic Cancer
Several risk factors associated with pancreatic cancer can be classified into exogenous and
endogenous types. Smoking, alcohol, diet, and workplace exposure are some of the examples of
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exogenous risk factors. Inherited predisposition of family history, Peutz-Jeghers syndrome,
familial atypical multiple mole melanoma (FAMMM) syndrome, hereditary nonpolyposis
colorectal cancer (HNPCC), hereditary pancreatitis, chronic pancreatitis, and diabetes mellitus are
categorized as the endogenous risk factors [75].
The risk of pancreatic cancer associated with cigarette smoking is 1.74-fold higher than the
non-smokers [77]. Incidence of type II diabetes increases the risk 1.8-fold, and it is even worse in
cases of newly diagnosed diabetes with an increased risk of 2.9-fold [78, 79]. Individuals with
body mass index (BMI) of >35 have a 1.55 fold higher risk than the ones with BMI of 18.9-24.9
[80]. Rate of heavy alcohol consumption (more than six drinks a day) is also linked to higher
incidence of pancreatic cancer with 1.46-fold increased risk than compared to cases with one drink
per day [81].
The rate of incidence of pancreatic cancer in the African-Americans population is relatively
higher [82]. The adjusted rates of pancreatic cancer in African American males are 17.5 per
100,000 whereas in white males the rates are 13.5 per 100,000. Similarly in females the rates are
14.8 per 100,000 in African American and 10.5 per 100,000 in white females [82].
1.6.2. Pancreatic Cancer Progression: From a Histological Perspective
Pancreatic ductal adenocarcinoma is the predominant form of pancreatic cancer which
comprises more than 95% of pancreatic cancer. Similar to other types of epithelial cancers,
pancreatic cancers do not arise de novo but undergo a series of stepwise development from
premalignant lesions to invasive cancer. The three non-invasive forms of pancreatic cancer are: 1.
pancreatic intraepthelial neoplasia (PanIN), 2. mucinous cystic neoplasm (MCN), and 3.
intraductal papillary mucinous neoplasm (IPMN) [83]. PanINs are the most common type of
precursor lesions in pancreatic cancer and are detailed below.
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The standard nomenclature and classification of the precursor lesions are based on the
grades of “pancreatic intraepithelial neoplasia” (PanIN). PanINs are small microscopic lesions in
the smaller pancreatic ducts, which are less than 5 mm and are morphologically classified into
three types: PanIn-1 (low-grade PanINs), PanIN-2 (intermediate grade PanINs), and PanIN-3
(high-grade PanINs) which further advances to the invasive carcinoma [83].
The histopathological features of each stage is shown in Figure 1.10. PanIN 1 can be either
flat (1A) or papillary (1B). The nuclear polarity and round morphology of nucleus in the cells are
conserved in PanIN-1 stage. The lesions in PanIN-2 bear more nuclear abnormalities, loss of
nuclear polarity, pleomorphism (differences in size of nucleus), nuclear hyperchromasia (increased
DNA content), and nuclear pseudostratification. Mitoses are generally not seen. PanIN-3 is also
called as “carcinoma-in situ”. Features of this lesion include enlarged nuclei, budding of clusters
of cells in the lumen, recurrent mitoses, dystrophic goblet cells with nucleus towards the lumen
and mucinous cytoplasm towards the basement.

Figure 1.10. Histological images of benign pancreatic ductal cells, PanIN lesion and invasive
carcinoma [84].
1.6.3. Abnormal Signaling Pathways in Pancreatic Cancer
Besides the histo-pathological changes in features, distinct genetic mutations occur in each
grade of PanINs. Activation of Kristen Rat sarcoma virus oncogene homolog (KRAS), inactivation
of INK4A, and depletion of tumor suppressor TP53 and Mothers against decapentaplegic homolog
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4 (SMAD4) are some of the successive genetic mutations occurring in the process of progression
of pancreatic tumors [85]. Pancreatic cancer harbors deregulation of 12 core signaling pathways
with 63 types of abnormal genetic changes [86]. Some of the molecular pathways that are involved
in survival, proliferation, progression, and the metastasis of pancreatic cancer are discussed below:
1.6.3.1. The Ras Activated Pathway
Mutations and deregulation in the KRAS signaling pathway are very common phenomena
identified in 90% of pancreatic cancer [86-88]. KRAS mutation occurs in a very high frequency
in PC [89, 90]. Mutation in the KRAS oncogene is one of the earliest events that take place in the
progression towards the development of PC [91].
The Ras protein is localized at the inner wall of the cell membrane and acts as a principal
signal regulator. It is encoded by the human RAS genes. In a normal physiological condition, the
Ras protein usually cycles between “GDP-bound inactive state” and “GTP-bound active state”.
This cycle is regulated by the Guanine-nucleotide exchange factors (GEFs) and GTPase-activating
proteins (GAPs). The schematic diagram of this process is illustrated in Figure 1.11. The GEFs
promote Ras activation by assisting in the exchange of GDP for GTP whereas GAPs hydrolyze
the GTP and thus cause inactivation of Ras protein. On reception of signals from the growth
factors, the bound GDP is removed by GEFs and activation of Ras protein occurs with binding to
GTPs. The GTP bound Ras protein can further trigger kinase activity of down-streaming effector
molecules like the Raf family of proteins and eventually initiate the MAPK cascade. This cycle of
activation is terminated by GAPs, which converts GTP bound Ras to a GDP bound inactive form.
But in cancer cells, Ras proteins are frequently mutated (single point mutations at residues G12,
G13 or Q61) and because of these mutations, the Ras proteins are often insensitive to GAP activity
which results in a constant GTP bound active state.

26

Activation of Ras protein is associated with, but not limited to the mitogen-activated
protein kinase (MAPK), the Rapidly Accelerated Fibrosarcoma (RAF)/MAPK/ERK kinase
(MEK)/ Extracellular signal-Related Kinase (ERK), and the Phosphatidylinositol 3-kinase
(PI3K)/AKT signaling pathways for cellular proliferation, transformation and apoptosis.
Aforementioned pathways are the key pathways activated in pancreatic cancer because of the
frequent KRAS mutation and are briefly discussed below.

Figure 1.11. The cycle of Ras protein in normal cells and in pancreatic cancer cells. The
activated state is GTP bound and the inactive state is GDP bound. Proteins like GEF and GAP
aid in regulating the activation cycle of Ras protein.
1.6.3.2. The Ras/Raf/MAPK Signaling Pathway
The oncogenic Ras/Raf/MAPK pathway plays an important role in cancer cell growth and
division, differentiation and migration, tissue healing and angiogenesis [92]. The Raf family
proteins consists of serine/threonine kinases which bind to activated Ras. This further stimulates a
series of phosphorylation and activates kinases belonging to the MAPK family including MEK
1/2, ERK1/2. Finally, the activated ERK1/2 translocate to the nucleus and activates transcription
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factors and stimulates expression of growth factors, cytokines or growth regulators such as cyclins
resulting in continuous proliferation of cancer cells. Cyclin D1, signal transducer and activator of
transcription (STAT3), nuclear factor kappa B (NF-κB), and cyclooxygenase-2 (COX-2) are some
of the downstream molecules linked to the ERK pathway [93]. It has been demonstrated that
inhibition of these kinases result in cell cycle arrest and decreased proliferation of PC cells [94].
Currently there are thirteen ongoing clinical trials with MEK inhibitors in pancreatic cancer [79].
1.6.3.3. The PI3K/Akt Pathway
Even though KRAS is such a major element in PC, therapy directed at its expression has
not been successful [95]. The other pathway that is activated with activated Ras is the PI3K/Akt
pathway. The activated Ras complex can activate PI3K [96] which phosphorylates membrane
bound phosphatidylinositol (3, 4)-biphosphate (PIP2) and forms phosphatidylinositol (3, 4, 5)trisphosphate (PIP3). The phosphorylated PIP3 then attracts Akt or Protein Kinase B to the cell
membrane [97]. Akt are a family of serine/threonine protein kinases that once phosphorylated
further phosphorylates multi-targets. Once activated, Akt affects various downstream processes
such as inhibition of apoptosis [98], activation of protein synthesis [99], inhibition of tumor
suppressor proteins like Forkhead box O (FOXO3A) [100], stimulation of glucose uptake [101],
and promotion of angiogenesis. In most of the cancers, the expression of PI3K and Akt is very
high and is of major importance. Therefore targeting PI3K/Akt and MAPK signaling pathways is
of great importance in anti-cancer therapy [102, 103]. There are at least 27 ongoing clinical trials
with drugs aimed at targeting the PI3K/Akt pathway in pancreatic cancer [79].
1.6.3.4. The Epidermal Growth Factor Receptor (EGFR) Signaling Pathway
The epidermal growth factor family of receptors also plays a major role in pancreatic cancer
cell growth and progression. There are four types of receptors within this family; EGFR1, HER2,
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EGFR3 and EGFR4. The expression of these receptors is highly upregulated by KRAS and has
shown to be crucial in KRAS associated carcinogenesis of the pancreas [104]. Its overexpression
is associated with advanced disease, poor survival and metastatic pancreatic cancer [105]. The
EGFR family possess a strong ability to activate both the MAPK and PI3K pathways. Pancreatic
cancer MIA Paca-2 cells have been found to extensively express these receptors [106]. Figure
1.12. represents the schematic overview of pathways and cross talk involved with expression of
EGFR.

Figure 1.12. Schematic diagram of dysregulated expression of EGFR and oncogenic KRAS.
Activation of the Ras/Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways is linked to
pancreatic cancer. Adapted from Eser et al. [107].
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1.6.3.5. Irregular Metabolism
KRAS oncogenes are also reported to be responsible for stimulation of genes responsible
for glycolysis and glutaminolysis [108]. Normal differentiated cells depend upon mitochondrial
oxidative phosphorylation for energy production but rapidly proliferating cancer cells undergo
aerobic glycolysis which is also called the Warburg effect. Activation of NF-κB is also linked to
increased Warburg effect in cancer cells. Increased Warburg effect is considered one of the
hallmarks of cancer [109]. High NF-κB activity in cancer cells is also associated with down
regulation of apoptotic proteins and development of chemo-resistance [110]. Therefore targeting
NF-κB is one of the major steps towards drug development against cancer [111].
In normal cells, in the presence of oxygen, pyruvate generated by glycolysis is metabolized
via the tricarboxylic acid (TCA) cycle generating CO2 and adenosine triphosphate (ATP), but in
absence of oxygen, pyruvate is converted to lactate, whereas in cancer cells, regardless of the
presence or absence of oxygen, about 85% of pyruvate is metabolized to form lactate with very
low generation of ATPs [66]. Previously, the process was misinterpreted that cancer cells have
defective mitochondria, which was the reason for dependence of cancer cells in glycolytic process
[112]. High rate of glycolysis is not efficient for cancer cells in terms of ATP production, however
the glycolytic intermediates formed are used by the cancer cells for the synthesis of nucleotides,
amino acids, and lipids, which are molecules required for the foundation of cellular structure and
function [66].
Cancer cells harboring the Ras oncogene have high rates of glycolysis and the expression
of glucose transporter GLUT1 facilitates a higher uptake of glucose [112]. Hexokinase, pyruvate
kinase and lactate dehydrogenase are some of the many enzymes involved in the glycolytic
pathway and account for the conversion of phosphoenolpyruvate to pyruvate and lactate. It has
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been suggested that targeting these enzymes can inhibit the Warburg effect, one of the hallmarks
of cancer [113].
Despite knowledge about molecular mechanism of PC, there is a limited progress in
effective drug development because PC is highly resistant to therapeutic agents. Therefore there is
a dire need in the improvement of pancreatic cancer research by finding for better
chemotherapeutic approaches. Since oncogenic regulation of KRAS is one of the main common
changes found in PC, studies are more focused towards targeting KRAS.
1.6.4. Therapeutic Approaches to Pancreatic Cancer
Treatment options for pancreatic cancer vary depending on the stages of tumor. The sign
and symptoms for pancreatic cancer include indigestion, nausea, weight loss, back pain, jaundice
and abdominal pain. These symptoms could be misinterpreted as signs of other diseases and
dysfunctions. That is why, by the time a patient is diagnosed with pancreatic cancer, the median
size of the tumor is already about 3.1 cm [114]. For a surgical resection, pancreatic tumors usually
have to be less than 2 cm in diameter and without advanced metastasis [115]. As a result only 1520% of the cases can be resected at the time of diagnosis [116]. Even after undergoing surgical
resection, the 5-year survival rate of the patients is 20% [117]. Adjuvant therapies, chemoradiotherapy followed by chemotherapy is provided to patients for prolonged survival after
resection [118].
For locally advanced or metastatic pancreatic cancer, surgical resection is not suitable;
rather chemotherapy is considered. Among various chemotherapeutic agents, gemcitabine is
considered as the first line standard chemotherapeutic treatment approved by the FDA for
advanced and metastatic pancreatic cancer [119]. Some of the other drugs that are administered
for treatment of pancreatic cancer are FOLFOX, and FOLFIRINOX [120]. Gemcitabine only
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increases the median survival from 4.5 months to 6 months [121]. Therefore to attain better clinical
benefits of gemcitabine for a prolonged survival, several clinical trials have been carried out
combining gemcitabine with other chemotherapeutic agents like cisplatin [122] and paclitaxel
[123]. The combination therapy has proven to be better than gemcitabine alone, but still the rate
of overall improvement is still low with deleterious side effects [124]. As a result there have been
serious ongoing efforts in discovery of novel compounds for treatment of pancreatic cancer with
better advantages. In this regard, bioactive components from plants and herbs are studied as the
source of pharmaceutical agents.
1.6.5. Dietary Chemo-preventive Agents against Pancreatic Cancer
Anti-cancer properties of various dietary bio-actives from fruits, vegetables, nuts, or spices
have been reported in literature. A recent review by Azimi et al. have summarized the data on the
use of phytomedicine for the treatment of pancreatic cancer up to the year 2013 [120].
Phytochemicals have been shown to target the disease and are known for the ability to modulate
various abnormal cell signaling pathways associated with cancer [125]. For that reason
modification of dietary pattern can help prevent various forms of cancer including pancreatic
cancer [126]. The common targeted mechanisms of phytomedicines in pancreatic cancer include
antiangiogenic, autophagy, cell cycle arrest, cytotoxic, anti-metastatic, cytotoxic, and apoptotic
activities [120].
There are 12 different frequently studied flavonoids namely; apigenin, genistein, quercetin,
resveratrol [127], epigallocatechin gallate [128, 129], benzyl isothiocyanate, sulforaphane [130],
curcumin [131], thymoquinone, dihydroartemisinin, cucurbitacin B and perillyl alcohol that target
pancreatic cancer via 4 or more mechanisms [120]. These findings confirms the beneficial
properties of phytochemicals. Many of the phytochemicals are already in human clinical trials with
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positive outcome. For instance extract of ukrain (extract of Chelimodium majus) was shown to
improve the quality of life of pancreatic cancer patients and also when given in combination with
gemcitabine doubled the survival time [132] and extract of garlic was found to improve the activity
of NK cells [133]. Cancer treatment and prevention using dietary phytochemicals has gained
attention for their availability and essential biological activity.
1.7. Research Objective and Specific Aims
The main objective of this doctoral dissertation research is to evaluate the cytotoxic effect
of bioactive natural quinoid compound juglone and to provide a better understanding of its effect
on molecular mechanism associated with human pancreatic cancer. The molecular biology
involved in the pathogenesis of pancreatic cancer has been considered in order to investigate the
properties of juglone as an anti-cancer agent. Based on the evidence provided in the literature
[134], targeting KRAS related signaling molecules can be a promising therapeutic strategy against
pancreatic cancer and chemo-resistance [135]. We hypothesized that juglone acts as a cytotoxic
agent against pancreatic cancer cells through down-regulation of critical oncogenic markers. The
goal of this project was achieved with the following three specific aims:


Aim 1: Screen the cytotoxic effect of juglone at various concentrations and determine the
IC50 value in pancreatic adenocarcinoma cells



Aim 2: Evaluate the mode of action and analyze the therapeutic efficacy of juglone in
various signal transduction markers associated with pancreatic cancer



Aim 3: Investigate the anti-angiogenic and anti-metastatic potential of juglone and
examine its effect on modulation of key angiogenic factors active in PC cells
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CHAPTER 2. CYTOTOXICITY OF JUGLONE AND THYMOQUINONE AGAINST
PANCREATIC CANCER CELLS
2.1. Introduction
The mortality rate due to pancreatic cancer in both men and women is very high [1]. For
instance, in 2015 the estimated new cases of pancreatic cancer in the United States for male and
female were 24,840 and 24,120 and the number of deaths for male and female were estimated to
be 20,710 and 19,850 respectively [1]. The median five-year survival rate for pancreatic cancer
patients is less than 5% [2]. Pancreatic cancer is usually diagnosed at an advanced stage and
gemcitabine is the first-line chemotherapeutic agent that is used for the treatment [3]. The tumor
response rate to gemcitabine is reported to be <10% [3] with a survival benefit of 5.8 months only.
Moreover due to the development of chemo-resistance associated with the use of this drug, there
is a very limited clinical benefit [4]. Therefore, there is an unmet need in the field of drug discovery
processes for treatment of pancreatic cancer and novel strategies are required.
Juglone (5-hdroxy-1, 4-napthoquinone) is a naphthoquinone found in leaves, roots, husks
and barks of the plants in the Juglandaceae family. Juglone is formed through the shikimic acid
pathway [5]. It is basically dark orange-brown in color and is also used as a coloring agent. The
concentration of juglone in the husk is 1.54-1.66 mg/g [6]. Juglone has anti-tumor effects on
ovarian cancer cells [7], breast cancer cells [8], prostate cancer cells [9], colon cancer cells and
cervical cancer cells [10]. However, the anti-proliferative effect of juglone in human pancreatic
MIA Paca-2 cells has never been demonstrated.
Combinatorial effect using juglone in conjunction with thymoquinone (TQ) in PC cells
survival is studied. TQ is a principle active component of Nigella sativa seeds’ oil which belongs
to Ranunculaceae family, and is considered as a compound of interest for its potential medicinal
properties. It has been reported to be used in traditional medicine for the treatment of dysentery,
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asthma, gastrointestinal diseases, hypertension and obesity [11]. TQ has also been proven to have
antitumor activities in various kinds of cancers such as breast, colon, ovarian, lungs, and larynx
[12] including pancreatic cancer [13].
The primary objectives of this research were to examine the effect of juglone on cell growth
inhibition, colony formation, and apoptosis induction in pancreatic cancer MIA Paca-2 cells. The
effect of juglone in combination with thymoquinone (TQ) was also investigated.
2.2. Materials and Methods
2.2.1. Reagents
Juglone, thiazolyl blue tetrazolium bromide (MTT), crystal violet, dimethyl sulfoxide
(DMSO), and thymoquinone were purchased from Sigma Aldrich (St. Louis, MO); Trypsin
EDTA, Dulbecco’s Modified Eagle Medium (DMEM), Hoechst 3342, Phosphate Buffer Saline
(PBS), penicillin streptomycin was obtained from Invitrogen (Carlsbad, CA) and fetal bovine
serum was from Atlanta Biologicals (Flowery Branch, GA).
2.2.2. Cell lines and Culture Conditions
MIA Paca-2, PANC-1 and BxPC-3 are adherent epithelial type pancreatic carcinoma cell
lines from ATCC (the American Type Culture Collection) and were generously provided by The
William Hansel Cancer Prevention Laboratory, PBRC. As recommended by ATCC, the cell lines
were maintained in culture in DMEM supplemented with 10 % fetal bovine serum, penicillin and
streptomycin and grown at 37oC in a humidified incubator with 5% CO2 until 70-80% confluency.
After reaching confluency, it was split at the ratio of 1:3 to1:8. The growth medium was changed
2-3 times a week and 0.25% trypsin EDTA was used to detach the cells for subculture.
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2.2.3. Screening of Cytotoxicity
Stock solution of juglone was prepared in DMSO, the final concentration of DMSO when
in culture was < 0.1%. In order to determine the dose- and time- dependent cytotoxicity of juglone,
MIA Paca-2, BxPC-3, and PANC-1cells were plated at a cell density of 5 x103 cells/well in a 96well plate. After seeding overnight, cells were treated with juglone and incubated for 4 h or 24 h.
Cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT) assay. Cytotoxicity of juglone at 24 h was also tested against BxPC-3 and PANC-1.
After required incubation, 20 µl of MTT (5mg/ml) was added and incubated for 4 h.
Formazan product formed from MTT was dissolved with addition of DMSO and absorbance was
recorded at 590 nm. The number of viable cells is directly proportional to the absorbance at 590
nm. Cell viability results are shown as percentage of control. All experiments were performed in
triplicates. Data collected from cytotoxicity assay were used to calculate the IC50 value for juglone.
2.2.4. Morphological Changes
Juglone-treated MIA Paca-2 cells were observed under inverted microscope and images
were recorded at 10X magnification. To observe the change in nuclear morphology, cells treated
with or without juglone were first fixed with 4% (v/v) formaldehyde for 10 min at RT, washed
with PBS and stained with Hoechst 3342 (1 µg/ml) for at least 15 min. The nuclear morphology
was observed with a fluorescent microscope at 40X magnification.
2.2.5. Long Term Survival Colony Formation Assay
The method of Woolston et al. was used [14]. Logarithmically growing MIA Paca-2 cells
were plated at a density of 3.5 x 105 cells per well in a 6- well plate. After allowing the cells to
attach properly, cells were treated with juglone for 6 h. After treatment, juglone-treated and
untreated viable MIA Paca-2 cells (2x103) were immediately re-plated in a 6- well plate with fresh
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medium containing no treatments. Cells were incubated at 37oC in a humidified incubator with 5%
CO2. The plates were undisturbed during the entire incubation period and cells were allowed to
grow until colonies consisting of more than 50 cells were seen, which was equivalent to about 12
days for MIA Paca-2 cells.
After colonies were formed, growth media was aspirated and cells were washed with PBS.
Colonies were fixed with sufficient volume of methanol: saline (1:1) to cover the colonies and the
methanol: saline solution was removed after 15 min. Methanol (100%) was added to the colonies
and after 15 min colonies were stained with 0.5% crystal violet (CV) solution for at least 30 min
at RT. CV solution was aspirated and colonies were washed carefully with an indirect flow of
water. Plates were inverted and allowed to dry at RT. Experiments were conducted in triplicates.
Cell colonies containing at least more than 50 cells were counted manually. Retained CV by
colonies was dissolved with 33% acetic acid, optical density was read and results from juglonetreated colonies were compared to colonies formed with untreated MIA Paca-2 cells.
2.2.6. Detection of Apoptosis by Annexin V Staining and Propidium Iodide Labeling
To confirm apoptosis, the translocation and externalization of phospholipid
phosphatidylserine from cytoplasm to extracellular surface was detected by Annexin V staining
and PI staining [15]. Annexin V- FITC Apoptosis detection kit was purchased from Sigma. Cells
were plated in 6-well plates at a cell density of 350 K cells/well. After treatment with juglone for
24 h, cells were collected with 0.25% trypsin, centrifuged at 1000 rpm for 5 min and re- suspended
in the supplied binding buffer. Cells were stained with Annexin V-FITC following the
manufacturer’s protocol (Sigma). FITC (fluorescein isothiocyanate)-conjugated Annexin V was
added to the cell suspension at a ratio of 1:100 and propidium iodide (PI) at 1:50. Cells were
incubated for at least 10 min in the dark. Stained cells were analyzed by flow cytometry.
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2.2.7. Drug Combinatorial Effect of Juglone with Thymoquinone
Combination therapy is mostly used in the drug development process to target multi
oncogenic markers and avoid drug resistance. In this experimental design, the effect of the
combination of juglone and TQ on MIA Paca-2 cells was also evaluated. When two or more drugs
are combined, there are three possible outcomes with treatment; synergy, additive effect or
antagonist effect. There multi-drug effect was evaluated using the combination index method of
Chou and Talalay [16, 17].
In order to determine whether Jug had an additive, synergistic or antagonistic effect with
TQ first the IC50 for each drug had to be established. MTT Assay as described in section 2.2.2 was
performed using TQ to determine its IC50. The dose range that would be used for drug combination
was designed as explained by Chou and Talalay [17]. A total of six different concentration
combinations (at least two data points above and below the IC50 and a zero concentration) with
three replicates per condition were used. As recommended by Chou [16], ‘Constant combination
ratio’ was used where two drugs were mixed simultaneously at their respective IC50 value and
dilutions were made accordingly. For that, serial dilution of both drugs was performed yielding 4,
2, 1, 0.5, 0.25, 0.125 times the IC50 of each compound and MIA Paca-2 cells were treated at the
respective concentrations. After 24 h of incubation, MTT assay was performed as described earlier.
The affected fraction of cells after treatment was then calculated and the dose-effect curves
for juglone or TQ alone and for two-drug combinations juglone-TQ were created. Isobolograms
were made using the values for affected fraction of cells and combination index (CI) was also
determined using CompuSyn software. The CI value correlates with the effect of combination
treatment. A CI of < 0.9 is considered synergistic, a CI of ⩾ 0.9 or ⩽ 1.1 is considered additive,
and a CI of > 1.1 is considered antagonistic [17].
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The formula for CI for two drug combinations [16, 18] is:
CI =

CJug,50
CTQ,50
+
IC50,Jug IC50,TQ

Where CJug, 50 = Corresponding concentration of juglone at the IC50 level of drug combination
C TQ, 50 = Corresponding concentration of TQ at the IC50 level of drug combination
IC50, Jug or IC50, TQ = IC50 for juglone or TQ alone
2.2.8. Statistical Analysis
All the experiments were conducted in triplicates. Results are expressed as means ± SD of
experiments. Analysis of variance (ANOVA) was conducted to examine the differences between
treatments followed by Tukey analysis using SAS software (Cary, NC). A P-value of <0.05 was
considered to be statistically significant and indicated with different letters.
2.3. Results
2.3.1. Effect of Juglone on Pancreatic Cancer Cell Viability
To determine the effect of juglone in various types of human pancreatic cancer cells,
BXPC-3, Panc-1 and MIA Paca-2 cells were used. Cancer cells were treated with equimolar
concentration of juglone for 24 h. Results in Figure 2.1. show that juglone significantly inhibited
the growth and proliferation of all of the pancreatic cancer cells investigated. However, the
inhibitory effect of juglone was higher in MIA Paca-2 cells than BXPC-3 or Panc-1 and among
these pancreatic cancer cell lines MIA Paca-2 cells contains high level of mutant KRAS whereas
BxPC-3 has the wild type KRAS [19, 20]. Therefore, remaining experiments to achieve the
outlined aims of this study were done using MIA Paca-2 cells.
Figure 2.2. shows that juglone exhibited cytotoxic effect in MIA Paca-2 cells in a
concentration- and a time-dependent manner. In order to calculate the IC50 value of juglone in MIA
Paca-2 cells, MTT assay was performed. Cells were treated with at least seven different
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concentrations of juglone in a range of 0.5 μM-20μM for 24 h. Juglone significantly inhibited the
proliferation of MIA Paca-2 cells in a dose-dependent manner.

OD @590 nm expressed in terms of control

1.2

a

a

a

1

b

b
0.8

b
0.6

0.4
-

+

-

+

MIA Paca-2

-

Panc-1

+
BxPC3

Optical Density @590nm expressed in
terms of control

Figure 2.1. Comparative inhibitory effect of juglone (+) at equimolar concentration on the
proliferation of various types of pancreatic cancer cells.
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Figure 2.2. Concentration and time dependent inhibition of juglone on the growth of MIA Paca-2
cells.
Fractions of affected cells at various concentrations were calculated and a dose effect curve
was created as shown in Figure 2.3. The IC50 value of juglone in MIA Paca-2 cells was calculated
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using the concentration effect relationship and reported to be 5.05 μM. These data indicate that
juglone exerts concentration- and time- dependent growth inhibitory effect in pancreatic cancer
cells.
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Figure 2.3. Dose-effect curve of juglone on MIA Paca-2 cells on the basis of the results from the
MTT assay.
2.3.2. Juglone Induced Morphological Changes in Pancreatic Cancer MIA Paca-2 Cells
Results indicate that treatment with juglone controlled the proliferation of pancreatic
cancer cells. Morphological changes such as cell shrinkage, nuclear condensation and formation
of apoptotic bodies are observed in apoptotic cells. Chromatin condensation is one of the hallmarks
of apoptosis. As shown in Figure 2.4., untreated cancer cells had normal morphology, and
possessed cell to cell contacts, but when treated with juglone, the cells shrunk and rounded up, an
indication that cells underwent apoptosis.
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Control

Juglone (5μM)

Juglone (10μM)

Figure 2.4. Morphological changes in juglone-treated MIA Paca-2 cells. Images were recorded at
10X magnification.
The nucleus of cells treated with or without juglone for 24h was also observed by Hoechst
staining with a fluorescent microscope. Results of nuclear morphology as depicted in Figure 2.5.
indicate that the untreated cancer cells had intact nuclear architecture whereas presence of small,
condensed and bright nuclei and apoptotic bodies were seen in juglone-treated MIA Paca-2 cells
due to the cytotoxic effect of juglone.
2.3.3. Effect of Juglone on Colony Forming Ability of Pancreatic Cancer MIA Paca-2 Cells
Clonogenic assay has been widely used to assess the sensitivity of cancer cells to anticancer drugs. To determine long term effect of juglone on survival and proliferation, clonogenic
assay was performed. Results of colony formation assay are presented in Figure 2.6. and show that
there was a dose-dependent inhibition of juglone on clonogenicity of pancreatic cancer cells.
Formed colonies were stained with CV (Figure 2.6., A). Quantification of the colonies
formed were either done manually or using a spectrophotometer. Retained CV in the colonies was
dissolved using 33% acetic acid, optical density was measured, and results were expressed in
percentage of control (Figure 2.6., B). Colonies were also counted manually and the number of
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colonies formed are presented in Figure 2.6., C. MIA Paca-2 cells treated with juglone at 5 and 10
μM for 6 h significantly lost the ability to form colonies.
0 μM

1 μM

10 μM

5 μM

Figure 2.5. Changes in cellular and nuclear morphology of MIA Paca-2 cells upon treatment with
juglone. MIA Paca-2 cells were treated for 24 h and then fixed and stained with DNA binding
dye Hoechst 3342 (1µg/ml). Images were captured with a white field confocal microscope.
Differential interference contrast (DIC) gray scale images of cells with blue nuclei in blue color
are shown. Small, condensed and fragmented nuclei was observed in juglone-treated cells.
Juglone-treated cells lose their cellular integrity and appear smaller and less dense than the
untreated MIA Paca-2 cells. Arrows indicate chromatin condensation and apoptotic bodies. Scale
bar represents 10 µM.
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Figure 2.6. Suppressive effect of juglone on clonogenic ability of MIA Paca-2 cells. A.
Representative images of colony formation assay. MIA Paca-2 cells were treated with juglone
for at least 6 h and the treated cells were plated and incubated for 12 days. Formed colonies were
stained with crystal violet. B. Retained CV by the colonies were dissolved in 33% acetic acid and
optical density was measured at 590 nm and reported in terms of control. C. Colonies were also
manually counted and reported.
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2.3.4. Juglone Induced Apoptosis of MIA Paca-2 Cells
Apoptotic cell death was identified by double staining with FITC-conjugated Annexin V
and PI using flow cytometry. In a live cell, the phosphatidylserine molecules are located in the
inner surface of the cell membrane and are not accessible to the annexin molecules for binding as
illustrated in Figure 2.7. Externalization of the phosphatidylserine (PS) molecules from inner to
outer membrane in cells is a very common feature of cells in the early stage of apoptosis. Annexin
V is a special protein that specifically binds to the PS molecules, and when conjugated to
fluorescent dye like FITC, makes it possible for detecting apoptosis with a flow cytometer. When
cells die, they also lose membrane integrity, permeability in the plasma membrane mostly occurs
in the late stage of apoptosis. Dyes such as propidium iodide that only binds to the nucleic acids
of cells get access into the cell only during the late stage of apoptosis when the membrane of the
cells are permeable. Therefore, labeling cell with Annexin V and PI distinguishes and confirms if
cells are viable or are in an early or a late stage of apoptosis.

Figure 2.7. Schematic diagram demonstrating the principle of Annexin V and PI (propidium
iodide) staining.
MIA Paca-2 cells were treated with juglone at 1, 5 or 10 µM concentrations and co-stained
with Annexin V and PI. Cells in the early phase of apoptosis are located in the LR quadrant
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(Annexin V+ve/PI-ve), those in the late stage of apoptosis in the UR quadrant (Annexin V+ve/PI+ve),
and viable cells (Annexin V-ve/PI-ve) in the LL quadrant. The results as depicted in Figure 2.8.
show that apoptosis was observed in juglone-treated MIA Paca-2 cells within 24 h. Results from
flow cytometry are presented in dot-plot graph (Figure 2.8., A). The graph is divided into four
quadrants; Lower Left (LL), Lower Right (LR), Upper left (UL) and Upper Right (UR). The LL
quadrant represents Annexin V negative and PI negative cell population, the LR quadrant
represents Annexin V positive and PI negative cell population and UR quadrant represents both
Annexin V and PI positive cell population.
Our results show that when MIA Paca-2 cells were treated with increasing concentration
of juglone, the percentage of cells in the early and late stage of apoptosis increased simultaneously.
At 1 µM of juglone , ~42.31 % of cells were in the early stage of apoptosis, ~ 35.92% cells in the
late stage of apoptosis and ~20.13% cells were viable. When cells were treated with 5 µM of
juglone, ~52.09% of cells were in the early stage of apoptosis, ~68.06% cells in the late stage of
apoptosis and ~2.44% cells were viable. At 10 µM juglone, most of the cells were in the late stage
of apoptosis with ~14.63% in the early stage of apoptosis, ~85.05% in the late stage of apoptosis
and only ~1.16% cells were viable. These data strongly show that upon treatment with juglone
MIA Paca-2 cells undergo apoptosis.
2.3.5. Combinatorial Effect of Juglone and Thymoquinone
To determine the drug combination effect, first IC50 value of each compound was
determined by MTT assay. As described in section 2.3.1, IC50 value for juglone was found to be 5
μM. From the dose effect curve (Figure 2.9.), IC50 value for thymoquinone was found to be 24.15
μM. After determining the IC50 values, juglone and thymoquinone were mixed at a constant ratio
and combination index was determined at each concentration using Compusyn software.
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Figure 2.8. Juglone induces apoptosis in MIA Paca-2 cells. Cells were treated with juglone as
indicated and then stained with annexin V-FITC and PI. A. Results from flow cytometry analysis
are presented in a dot-plot graph. B. Percentage of apoptotic cells (in the early and late stage of
apoptosis).
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Figure 2.9. Dose-effect curve of thymoquinone against MIA Paca-2 cells on the basis of the
results from MTT assay.
The effect of juglone in combination with TQ is summarized in Tables 2.1., 2.2., and 2.3.
The IC50 value for juglone and TQ in combination was found to be 24.75 μM, which was higher
than juglone or TQ alone. At concentrations where 10, 20 or 50% of cells were affected, there
existed a moderate antagonistic relationship between juglone and TQ (Table 2.2.) as indicated by
the combination index (CI) value determined by the Compusyn software. At concentrations that
affected 75% and 90% of cells, there were nearly an additive effect with CI value of 1.09249 and
0.92391, respectively. Moderate synergism was only seen at concentration where 95% of cells
were affected, and the corresponding concentration of juglone and TQ at that combination was
40.8950 µM and 511.1870 µM respectively.
The graphical representation of combinatorial effect of juglone and TQ are also presented
via isobolograms (Figures 2.10. and 2.11.) that were created using Compusyn software. The nature
of interaction between two drugs can be evaluated by isobologram analysis as well in a two coordinate plot. The x and y coordinates in an isobologram represent the concentrations of individual
drugs required to produce a defined effect. Respective line connecting two data points in two
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different axes is the line of additivity. Points lying below the line of equivalency or line of
additivity in the isobologram indicate synergistic effect between two drugs and points above the
line of equivalency represent antagonistic effect [21]. The resulting isobolograms in our study
show that juglone and TQ act antagonistically at most of the concentrations and only exert some
synergy at very high concentration.
Table 2.1. IC50 values for juglone, thymoquinone and their combination in human pancreatic
cancer MIA Paca-2 cells
Drug
Juglone
Thymoquinone
Juglone + Thymoquinone

IC50 value (µM)
5.27353
24.1519
24.7545

m
0.89120
0.80316
0.94838

r
0.99055
0.99713
0.92373

Where m refers to the shape of the dose effect curve (m=1, >1, <1 indicate hyperbolic, sigmoidal and negative sigmoidal) and
r to the linear co-relation coefficient

Table 2.2. Assessment of combinatorial effect of juglone and thymoquinone at Fa: 0.1, 0.2 and
0.5. Combination index was determined by Compusyn software.
Fa
0.1
0.2
0.5

CI Value
1.84625
1.61803
1.29674

Total Dose
2.44049
5.73887
24.75447

Juglone (μM)
0.18078
0.42510
1.83367

Thymoquinone (μM)
2.25971
5.31377
22.9208

Table 2.3. Assessment of combinatorial effect of juglone and thymoquinone at Fa: 0.75, 0.90 and
0.95. Combination index was determined by Compusyn software.
Fa
0.75
0.90
0.95

CI Value
1.09249
0.92391
0.82626

Total Dose
78.8392
251.091
552.082

Juglone (μM)
5.8399
18.5993
40.8950

Thymoquinone (μM)
72.9992
232.4917
511.1870

2.4. Discussion
Recent advances in the use of phytochemicals for promoting health and reducing risk of
cancer have been documented in literature. Dietary bioactive compounds such as resveratrol [22],
curcumin [23], sulforaphane [24], epigallocatechingallate [25], piperlongumine [26] and others
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have proven efficacious in inhibiting the growth and proliferation of pancreatic cancer cells in
various in vitro and in vivo experiments.

Juglone (µM)

Fa=Fraction of affected cells

Thymoquinone (µM)

Figure 2.10. Juglone exerts an antagonistic relationship with thymoquinone at lower
concentrations. Isobologram was created with Compusyn software. The blue, red and green line
represents line of additivity at which there is 10%, 20% and 50% effect on the cells respectively.
Points lying above the line of additivity indicate antagonistic effect.

Juglone (µM)

Fa=Fraction of affected cells

Thymoquinone (µM)

Figure 2.11. Juglone exerts an additive and synergistic relationship with thymoquinone at higher
concentrations. Isobologram was created with Compusyn software. The blue, red and green line
represents line of additivity at which there is 75%, 90% and 95% effect on the cells respectively.
Points lying below the line of additivity indicate synergistic effect and points lying on the
equivalence line indicate additive effect.
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Many quinones-based drugs have been proven to be effective against cancer and are
already in clinical trials, which makes juglone an attractive compound to be explored against PC.
Quinones are abundantly found in nature; more than 1200 types of quinones have been reported in
literature [27]. They function as electron carriers in plants and are very well known for their redox
potential. Some of the various drugs against cancer that have been approved and those going
through clinical trials are quinones-based compounds such as actinomycin D, anthracyclines,
daunorubicin, menadione, mitomycin C, mitoxantrones, saintopin, and trenimon [28, 29]. This
shows the importance of naturally occurring quinones such as juglone in cancer research.
Abnormal growth and proliferation is an important characteristic of malignant tumors. In
this study, the effect of juglone on the proliferation and apoptosis of human pancreatic cancer MIA
Paca-2 cells was analyzed. We determined the IC50 value of juglone in pancreatic cancer MIA
Paca-2 cells to be 5.27 µM at 24 h. The IC50 value for juglone on ovarian cancer SKOV3 cells was
30.13 µM at 24 h [7]. Juglone has also shown to be effective against melanoma cells in a dose and
time dependent manner. The IC50 for juglone on B16F1 melanoma cells at 1, 24, and 48 h was 9.9
µM, 7.46 µM, and 6.92 µM, respectively [30]. Very high intracellular production of ROS was
linked to the mode of action of juglone mediated apoptosis in melanoma cells. These studies with
juglone on various cancer models show that the same compound reacts in different ways depending
upon the type of cancer and therefore it is very critical to establish the IC 50 values of juglone in
specific cell lines.
There are studies that have also utilized animal models to understand the anti-cancer effect
of juglone. In one study model, the dietary effect of juglone was investigated. When juglone was
administered at a concentration of 200 ppm, occurrence of multiple intestinal tumors was
significantly reduced in azoxymethane (carcinogen) –induced colon cancer rats [31]. Results

62

indicated that juglone had significant effect against tumor initiation and multiplication, but the
underlined mechanism was not been detailed. Another recent study conducted by Asano et al.
demonstrated that when LnCap tumor cells bearing mice were intraperitoneally injected with 40
µg of juglone once a week for 4 weeks, there was a significant reduction of tumor size and volume
with no significant reduction in weight of the mice [9]. These studies suggest that juglone as an
anti-cancer agent when administered in animal models proved to be safe and effective.
In this study we also investigated whether juglone induced apoptosis in pancreatic cancer
cells. Cancer cells evade apoptosis or “programmed cell death” by amplifying various antiapoptotic mechanisms, which leads to its uncontrollable growth, tumor progression and metastasis
[32]. Anti-cancer agents are known to induce apoptosis as well as inhibit cell growth and
proliferation of cancer cells [33]. The morphological changes that occur during apoptosis are cell
shrinkage, membrane blebbing, chromatin condensation and nuclear fragmentation [34]. Our
results clearly demonstrated that cells treated with juglone was positively stained with annexin V
and PI. As cells undergoing apoptosis have condensed chromatin, fluorescent dye such as Hoechst
is known to stain the nucleus of apoptotic cells more brightly than that of the normal cells [35],
and this phenomena of bright fluorescence in nucleus of apoptotic cells was also recorded in MIA
Paca-2 cells treated with juglone (Figure 2.5.). Morphological changes, cell shrinkage,
translocation of phosphatidylserine molecules were observed in MIA Paca-2 cells exposed to
juglone at concentration range of 1-10 µM; similar concentration of juglone has been reported to
cause increase in annexin V binding in juglone-treated erythrocytes [36] and cancer cells [37].
Colony formation assay was used to determine juglone associated long term inhibition of
the proliferation of MIA Paca-2 cells. As demonstrated in Figure 2.6., there was a significant
reduction in the number of colonies formed in juglone-treated pancreatic cancer cells in
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comparison to the untreated MIA Paca-2 cells. These findings are in line with other reports of
juglone treatment in other types of cancer. Studies performed by Pedrosa et al. showed a reduction
in the number of colonies in MCF-7 cells when treated with 10 µM of juglone [38].
The above findings indicate the cytotoxic effect of juglone on pancreatic cancer cells and
determine the effectiveness of juglone as an anti-proliferative agent against MIA Paca-2 cells.
Pancreatic cancer cell proliferation is regulated by juglone in a dose-dependent manner.
Drug combination studies was also carried out using juglone with TQ, the principal
bioactive component of the volatile oil of Nigella sativa (black seed). Each of these compounds
was demonstrated to be cytotoxic to MIA Paca-2 cells individually. Based on their cytotoxicity,
we hypothesized that combination treatment of MIA Paca-2 cells with juglone and TQ would result
in synergistic cytotoxicity. There are many in-vitro and in-vivo studies that have reported
synergistic action of TQ in conjunction with other phytochemicals such as EGCG against prostate
cancer [39], lycopene against cervical cancer [40], gemcitabine against pancreatic cancer [12],
doxorubicin against breast cancer cells [41], 5-fluorouracil against colon cancer [42], and many
more [40]. However, our results demonstrated that TQ in combination with juglone, did not exert
favorable synergistic relationship against pancreatic cancer cells. TQ acts as an anti-oxidant (free
radical scavenger) at lower concentrations and at higher concentrations acts as a pro-oxidant [43],
which might be one of the possible mechanisms that might be responsible for the antagonistic
effect between juglone and TQ as juglone induced cytotoxicity in cancer cells majorly involves
production of reactive oxygen species through redox activation [44]. Synergy between juglone and
TQ was only seen at very high dose combination where physiological concentrations of each
dietary bioactive compound could be very difficult to achieve.
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2.5. Conclusion
Inducing apoptosis in cancer cells is an important defense mechanism against cancer. Our
findings indicate that juglone exerts cytotoxic effect on pancreatic cancer MIA Paca-2 cells and
also controls its proliferation. The treated cells die through apoptosis and this has been confirmed
by Annexin V/PI staining. These data suggest that juglone may play a pivotal role in obstructing
pancreatic cancer development and progression. To further delineate the molecular mechanisms
of juglone-induced apoptosis of pancreatic cancer MIA Paca-2 cells, additional in vitro studies
were designed, performed and discussed in chapter 3.
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CHAPTER 3. JUGLONE MODULATES INTRACELLULAR LEVEL OF REACTIVE
OXYGEN SPECIES AND SUPPRESSES PANCREATIC CANCER PROLIFERATION
BY INHIBITION OF THE KRAS-DRIVEN SIGNALING PATHWAYS
3.1 Introduction
Despite the high incidence and mortality rate due to pancreatic cancer, progress in drug
discovery for an operative chemotherapeutic option has still not been very effective. One of the
challenges chemotherapy/radiotherapy faces in pancreatic cancer is the de novo chemo resistance
that pancreatic cancer cells develops [1]. Resistance to chemotherapeutic agents makes drug
development effort very crucial and therefore the identification of novel cytotoxic agents against
pancreatic cancer is much needed. Naturally occurring bioactives have played a significant role in
the drug discovery process and are recommended to be studied extensively for discovery of novel
source of efficient chemotherapeutic agents against cancer [2]. Among many bioactive compounds
present in nature, quinones comprise one of the largest group of compounds studied as anticancer
agents [3].
Juglone (5-hydroxy-1,4-naphthoquinone)is a naturally occurring naphthoquinone found in
the roots, leaves, nut-hulls, bark and wood of Juglans regia (English, Persian and California
walnut), J. cinerea,(butternut and white walnut) and J. nigra (black walnut). Juglone is known to
possess anti-tumor, anti-bacterial, anti-fungal anti-inflammatory and anti-parasitic activities [4-6].
Use of juglone-containing plants for therapeutic benefits has been documented in traditional
medicine practices for many years in countries like China and India [7, 8]. The anti-tumor activities
of naphthoquinones are primarily related to their pro-oxidant property [9].
Juglone inhibits a wide range of cancer cells and juglone inhibitory effect differs depending
upon cell type. Xu et al. has demonstrated that the cytotoxic effect of juglone on human leukemia
HL-60 cells was through reactive oxygen species (ROS)-dependent and mitochondria-dependent
pathways. Similarly, juglone was reported to induce ROS and cause apoptosis via mitochondrial
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mediated apoptosis in gastric cancer SGC-7901 cells [10]. There are no studies on the interaction
of juglone and pancreatic cancer cells. The aim of the present study was to investigate the
molecular mechanism of juglone induced cytotoxicity in human pancreatic cancer cells.
3.2. Material and Methods
3.2.1. Chemicals and Antibodies
Juglone, dichloro-dihydro-fluorescein diacetate (DCFH-DA), and dimethyl sulfoxide
(DMSO) were purchased from Sigma-Aldrich (St. Louis, MO). Primary antibodies against COX2 (#4842s), PARP (#9532s), Bax (#2772) and BCl-2 (#2876) were purchased from Cell Signaling
(Danvers, MA). Primary antibody against HER-2 (#21070-2) was purchased from SAB®
Signalway Antibody (College Park, MD). HRP conjugated secondary anti-rabbit antibodies and
bovine serum albumin were purchased from Santa Cruz (Dallas, TX). Trypsin EDTA, Dulbecco’s
Modified Eagle Medium (DMEM), phosphate buffer saline (PBS), penicillin streptomycin was
purchased from Invitrogen (Carlsbad, CA) and fetal bovine serum from Atlanta Biologicals
(Flowery Branch, GA).
3.2.2. Cell Culture
MIA Paca-2 cells were purchased from American Type Cell Culture. This cell line contains
mutation in KRAS genes with high levels of activated KRAS protein [11] and is appropriate for
the study, which is to target the down-stream molecules involved in the oncogenic KRAS pathway.
As recommended by ATCC, the cell line was maintained in culture in DMEM supplemented with
10 % fetal bovine serum, penicillin and streptomycin and grown at 37oC in a humidified incubator
with 5% CO2 until 70-80% confluency. After reaching confluency, it was split at the ratio of 1:3
to1:8. The growth medium was changed 2-3 times a week and 0.25% trypsin EDTA was used to
detach the cells for subculture.
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3.2.3. Measurement of ROS Production
Level of intracellular ROS with treatment was measured as previously described [12]. MIA
Paca-2 cells were plated in a black 96-well plate at a density of 10, 000 cells/well. After 24 h of
seeding, cells were treated with various concentrations of juglone. A stock of dichloro-dihydrofluorescein diacetate (DCFH-DA) (20mM) was prepared in DMSO. To determine the level of
intracellular ROS, supernatant was removed and replaced with 100 µM of DCFH-DA in PBS.
After 1h of incubation with DCFH-DA, cells were washed with freshly prepared Hank’s balanced
salt solution and fluorescence intensity was measured by a fluorescence reader using the excitation
wavelength of 485 nm and emission wavelength of 530 nm. Experiments were performed in
triplicate.
3.2.4. Western Blot Analysis
MIA Paca-2 cells were seeded at a density of 5 x105cells/well in a 6- well plate. After
seeding overnight, cells were treated with Juglone. Whole cell lysates were prepared by using cell
lysis buffer (Cell Signaling Technology (Danvers, MA) and supernatant were saved. Protein
concentrations of the samples were determined using the Bradford assay. Protein separation was
resolved in 4-12 % gradient Bis-Tris SDS polyacrylamide gels (Invitrogen, Carlsbad, CA) and
transferred to polyvinylidene difluoride (PVDF) membranes (Invitrogen, Carlsbad, CA).
Membranes were blocked with 5% BSA in PBS containing 0.05% Tween 20 (TBS-Tween) for 1h.
The PVDF membranes were then probed with primary antibody (Akt, Bax, Bcl-2, Cox-2, or HER2) in PBS-Tween containing 5% BSA overnight at 4oC with gentle agitation. Detection of protein
expression was done by probing the blots with horseradish peroxidase–conjugated secondary
antibodies (Santa Cruz) and exposure to chemiluminescent substrate (Thermo Fisher Scientific).
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Chemiluminescence was recorded by BioRad Imaging system and the densities of the bands were
quantified by Quantity One Software 1-D analysis software.
3.2.5. DNA Fragmentation Assay
Nuclear fragmentation and formation of apoptotic bodies occurs in cells undergoing
apoptosis. To demonstrate this process, the DNA fragmentation assay was performed. MIA Paca2 cells were plated at a density of 2×105 cells/well in 6-well plates and were treated with juglone
for 24 h. After required incubation, cells were collected by scraping and centrifuged. DNA of the
cells was then collected and purified using a genomic DNA extraction protocol [13]. Briefly, cell
pellets were suspended in Tris-EDTA (TE) buffer and 10% SDS buffer was added along with
proteinase K. The mix was incubated at 37oC for 1 h. After incubation, equal volume of
phenol/chloroform was added, mixed by inverting the tubes and incubated at 65oC for 10 min.
Phase separation was seen, the upper aqueous phase was collected and one tenth volume of sodium
acetate was added to the mix. Ethanol precipitation was done by adding 2 volumes of 100 %
ethanol and the samples were stored at -80oC overnight. The samples were centrifuged for 30 min.
The supernatants were discarded and 100% of ethanol was added to the pellet again and the mixture
was centrifuged for 15 min. The pellet was allowed to dry at 37oC and further dissolved in TE
buffer. Purified DNA was further separated using 1% agarose gel containing 0.5 µg/ml ethidium
bromide at 120 V, 50 A for 40 min. Gels were visualized under UV trans-illuminator and pictures
were captured. DNA from viable cells remained on the top of the gel whereas DNA from apoptotic
and necrotic cells formed ladder or smear.
3.2.6. Colorimetric Assay for Activated Caspase-3 Cell-Based ELISA
Caspase-3 activation was analyzed by using the LSBioTM Caspase 3-Cell Based ELISA kit
(Seattle, WA). Approximately, 2 x 104 cells were plated in a 96-well plate and allowed to attach
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overnight. Cells were then treated with juglone for 6h and after required incubation the media was
replaced, washed with PBS and fixed with 4% formaldehyde. Fixed cells were quenched and
blocked for at least 1h at room temperature. Cells were incubated overnight at 4oC with anticaspase-3 antibody at a dilution of 1:100. After overnight incubation cells were incubated with
HRP conjugated secondary antibodies for 1.5 h at room temperature, the substrate was added and
the mixture was incubated for 30 min at room temperature. Optical density was then read at 450
nm with a plate reader after addition of the stop solution. Once the readings were taken, cells were
then washed and further stained with crystal violet (CV) for 30 min. Stained cells in the plates
were washed with indirect flow of running water and TBS. Retained CV was then dissolved with
33% acetic acid and OD was measured at 595 nm. The readings at 450 nm were then normalized
with CV readings at 595 nm of the respective wells. Results are expressed in percentage of control.
3.2.7. Determination of phospho-ERK by Cell- Based ELISA
In order to determine whether juglone inhibited the phosphorylation of ERK, the level of
p-ERK/ERK was measured by a cell-based ELISA using a kit from R&D Systems (Minneapolis,
MN). MIA Paca-2 cells were plated in a black 96-well plate at a cell density of 1x104 cells per
well. After allowing to attach overnight, cells were treated with juglone for 6h. After required
incubation, the media was removed and the cells were washed with PBS. Immediately the cells
were fixed with 4% formaldehyde for 15 min. After 15 min fixation, the cells were washed with
PBS and endogenous peroxidase activity of the cells was blocked by incubation with 30%
hydrogen peroxide for 15 min. The cells were incubated with blocking buffer for 1 h, washed with
PBS at least 3 times and incubated overnight at 4oCwith phospho-ERK and total ERK antibodies.
After incubation with primary antibodies, secondary antibodies either conjugated to HRP or AP
(alkaline phosphatase) were added and incubated at room temperature for at least 2 h. Substrates
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provided in the kit were added to each well and fluorogenic detection was done using a
fluorescence plate reader (Perkin Elmer, MN). Readings with excitation at 540 nm and emission
at 600 nm represented the amount of phosphorylated ERK and readings with excitation at 360 nm
and emission at 450 nm represented the amount of total ERK in the cells. The readings were
expressed as the normalized value of the amount of phosphor-ERK fluorescence to that of total
ERK fluorescence.
3.2.8. Kinase Activities
The effect of juglone on enzymes that are actively involved in glycolysis including
hexokinase and pyruvate kinase was studied by determining hexokinase or pyruvate kinase
activity. Hexokinase activity was determined using a colorimetric kit from Sigma-Aldrich (St.
Louis, MO). Pyruvate kinase colorimetric was determined using a kit from Abcam® (Cambridge,
MA). Protein concentration of cell lysates was measured and glycolytic enzymes activities were
measured. Enzyme activity was measured accordingly at the respective wavelength. Hexokinase
activity was measured at 450 nm and pyruvate kinase at 570 nm.
∆OD450 or 570 (Optical Density at 450 nm or 570 nm) = A2-A1, where A2 and A1 are final
and initial absorbance at 450 nm or 570 nm respectively. Then amount of NADH or Pyruvate
generated (B) at the respective ∆OD450 or ∆OD570 was calculated and enzyme activity was then
finally calculated. Enzyme activity (nmol/min/ml or milliunit/ml) = B/ (∆T×V) × dilution factor,
where B is the amount of NADH generated (nmol) in case of hexokinase activity or amount of
pyruvate generated in case of pyruvate kinase activity, ∆T is the reaction time (min), and V is the
sample volume added (ml).
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3.2.9. Statistical Analysis
All the experiments were conducted in triplicates. Results are expressed as means ± SD of
experiments. Analysis of variance (ANOVA) was conducted to examine the differences between
treatments followed by Tukey analysis using SAS. A P-value of < 0.05 was considered to be
statistically significant. Means with different letters indicate significantly different
3.3. Results
3.3.1. Juglone Induced ROS Production in Pancreatic Cancer MIA Paca-2 cells
The level of intracellular production of ROS in MIA Paca-2 cells after treatment with 1, 5
or 10 µM juglone was detected by the DCFH-DA method. There was a 1.48-, 1.81- and 1.72- fold
increase in fluorescence, respectively (Figure 3.1.). There was a significant increase in the
generation of ROS in juglone-treated cells, the level of ROS at 5 and 10 µM of juglone treated
cells were significantly higher than in the untreated control group.
3.3.2. Juglone Activated Caspase-3 and Caused PARP Cleavage in MIA Paca-2 cells
Results of caspase-3 colorimetric assay indicate that juglone significantly induced caspase3 activation in a dose dependent manner (Figure 3.2., A). As the activation of caspase-3 was
observed in juglone-treated cells, we next determined whether PARP, a substrate for caspase-3
was cleaved. PARP cleavage is indicative of caspase-mediated cell apoptosis [14]. PARP assists
the DNA repair mechanism in cancer cells, and when cleaved by caspases they lose their
functionality [15]. Western blot analysis of PARP in juglone-treated cells clearly showed the
presence of cleaved fragments of PARP and the intensity of PARP increased as juglone
concentration increased starting at 1µM concentration (Figure 3.2., B). These results suggest that
juglone-induced apoptosis in MIA Paca-2 cells is the result of activation of effector caspase,
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caspase-3 and cleavage of PARP, which ultimately results in biochemical and morphological
changes seen in apoptotic cells.
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Figure 3.1. Intracellular measurement of reactive oxygen species (ROS). The levels of
intracellular reactive oxygen species in pancreatic cancer cells treated with juglone were
determined by dichloro-dihydro-fluorescein diacetate (DCFHDA) assay. Data represent average
of triplicates ± SD.
3.3.3. Juglone Induced DNA Fragmentation in MIA Paca-2 cells
Apoptosis in juglone treated MIA Paca-2 cells was also characterized by the DNA
fragmentation assay. Genomic DNA from juglone-treated and untreated MIA Paca-2 cells were
isolated and separated by agarose gel electrophoresis. Visualization of ethidium bromide bound
DNA fragments were done under UV illumination. Fragmentation of DNA was observed in
juglone-treated cells (Figure 3.2, C). These results also confirmed that dose-dependent apoptosis
occurred in MIA Paca-2 cells when exposed to juglone.
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Figure 3.2. A. Juglone-mediated activation of caspase-3 in MIA Paca-2 cells as measured by
cell- based ELISA. B. PARP cleavage in cells treated with juglone as demonstrated by Western
Blot. C. Chromosomal DNA ladder formation in cells treated with juglone following agarose gel
electrophoresis under UV. Lane 1: DNA from MIA Paca-2 cells without juglone, Lane 2 and 3:
DNA from juglone-treated (5 and 10 μM) MIA Paca-2 cells.
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3.3.4. Juglone Modulated the Expression of Pro-apoptotic Protein Bax and Anti-apoptotic Protein
Bcl-2
The BCl-2 family of proteins includes pro-apoptotic and anti-apoptotic proteins, which are
primarily involved in the regulation of apoptosis. To further explore the mechanism of apoptosis,
the characterization of Bax and Bcl-2 protein levels in juglone-treated MIA Paca-2 cells at 1 µM
and 5µM was done by western blot analysis. When compared with the untreated group, juglonetreated group of MIA Paca-2 cells showed significant downregulation of anti-apoptotic Bcl-2 and
upregulation of pro-apoptotic Bax (Figure 3.3., A). The ratio of Bcl-2 to Bax decreased by 37.5%
and 61.40% in 1 and 5 µM of juglone-treated MIA Paca-2 cells, respectively. Densitometric
analysis of expression of Bax and Bcl-2 is presented in Figures 3.3., B and 3.3., C, respectively.
3.3.5. Effect of Juglone on EGFR Signaling and Downstream pAKt and pERK Pathways in MIA
Paca-2 cells
Results in Figure 3.4 show that treatment of MIA Paca-2 cells with juglone resulted in a
dose-dependent decrease in HER-2 expression. Both full length HER2 and p95HER-2 were
downregulated with increasing concentrations of juglone. HER-2 down streaming pathways
include Akt and MAPK pathways, which are highly upregulated in pancreatic cancer cells. The
phosphorylation levels of Akt or Erk were determined. Juglone inhibited the phosphorylation of
Akt (Figure 3.5.) and Erk (Figure 3.6.) in MIAPaca-2 cells
3.3.6. Juglone Downregulated COX-2 in MIA Paca-2 Cells
Western blot analysis of cell lysates from juglone-treated cells showed that juglone at
concentrations 1, 5, or 10 µM significantly downregulated the expression of COX-2 in MIAPaca2 pancreatic cancer cells (Figure 3.7., A). Densitometric analysis of the bands further elucidated
the dose-dependent inhibition of COX-2 expression (Figure 3.7., B).
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Figure 3.3. Effect of juglone in expression of Bcl-2 family proteins in MIA Paca-2 cells. A. MIA
Paca-2 cells were treated with juglone at 1 and 5 µM for 6 h. After incubation cells were lysed
and subjected to western blot analysis of Bcl-2 and Bax. For loading control, β-actin was used.
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Figure 3.4. Juglone inhibits HER-2 shedding in pancreatic cancer MIA Paca-2 cells. A. Cells
were lysed and the 30 µg of whole cell lysate was subjected to western blot analysis. Basal level
of both full length (p185 HER-2) and truncated (p95 HER2) forms of HER-2 were inhibited with
treatment of juglone. B. Densitometry analysis of the bands are expressed in terms of untreated
control.
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Figure 3.5. Effect of juglone on the phosphorylation of Akt. MIA Paca-2 cells were plated in
black 96-well plate and treated with juglone (5 µM and 10 µM) for 6 h. After required incubation
cells were fixed and p- Akt in cells was measured using Phospho-Akt Cell based ELISA.
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Figure 3.6. Effect of juglone on the phosphorylation of ERK. MIA Paca-2 cells were plated in
black 96 well plate and treated with juglone (1 µM, 5 µM, or 10 µM) for 6 h. After required
incubation, cells were fixed and p- Akt in cells was measured using Phospho-ERK Cell based
ELISA.
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Figure 3.7. Effect of juglone on the expression of COX-2 in pancreatic cancer MIA Paca-2 cells.
MIA PAca-2 cells were treated with juglone at 1, 5, or 10 µM. A. Whole cell lysates were
prepared and 30 µg of cell lysate was subjected to western blot analysis. B. Densitometric
analysis of the bands using Quantity One software was done and results are expressed in terms of
untreated control.
3.3.7. Juglone Inhibits Aerobic Glycolysis via Downregulation of Hexokinase
The influence of juglone on enzymes involved in glycolysis was also investigated in this
study. Results in Figure 3.8 indicate that juglone dose-dependently inhibited glycolysis by
downregulating the expression of hexokinase in MIA Paca-2 cells. However, at similar
concentration juglone had no effect on pyruvate kinase (Figure 3.9.).
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Figure 3.8. Effect of juglone on the activity of hexokinase MIA Paca-2 cells were treated with
juglone for 6 h. Whole cell lysates were collected and hexokinase activity was measured.
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Figure 3.9. Effect of juglone on pyruvate kinase activity. MIA Paca-2 cells were treated with
juglone for 6 h. Whole cell lysates were collected and pyruvate kinase activity was measured.
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3.4. Discussion
In the present study the molecular mechanism behind juglone-induced cytotoxicity in
pancreatic cancer MIA Paca-2 cells was investigated. In a previous study it was shown that juglone
inhibited the proliferation and exerted cytotoxic effect in pancreatic cancer MIA Paca-2 cells with
an IC50 of 5.05 µM. To confirm that the cytotoxic effect of juglone was induced by apoptosis,
juglone treated cells were analyzed for DNA fragmentation assay, caspase activation and
expression of pro-apoptotic and anti-apoptotic proteins. Results indicate that juglone increased
caspase-3 activation, which in turn cleaved PARP, induced DNA fragmentation, increased the
expression of Bax and inhibited Bcl-2.
Results also indicate that juglone induced almost a 2-fold increase in ROS generated by
MIA Paca-2 cells (Figure 3.1.). A 2-fold increase in ROS production is very high [16]. ROS that
are produced by mitochondria usually include superoxide anions (O2-), hydroxyl radicals (.OH),
hydrogen peroxides (H2O2), and peroxynitrite (ONOO-) [17]. The role of ROS against cancer cells
have been studied extensively [18, 19]. Cancer cells are found to have a higher concentration of
endogenous ROS than normal cells [20] and the endogenous level of ROS assists cancer cell in
proliferation and survival through MAPK pathway and DNA damage [21]. When ROS production
is further induced in cancer cells, the disproportional increase of ROS leads to cell cycle arrest,
senescence and apoptosis, and is a direct way of specific-targeting of cancer cells [22, 23]. Juglone
caused a disproportionate increase in ROS leading to MIA Paca-2 cells apoptosis. Single electron
reduction causes juglone to form semiquinone radicals which are catalyzed by enzymes like
NADPH-cytochrome P45 reductase. The semiquinone radicals are capable of reducing molecular
oxygen to form the anion radical (O2.-). Further enzymatic reaction with O2. - forms other reactive
species like H2O2 and OH. [24]. This excessive generation of ROS leads to oxidative stress in cells
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and eventually causes apoptosis. Other studies have reported that juglone-induced ROS production
in cancer cells could cause apoptosis of gastric cancer cells [10], leukemia cells [7], or breast
cancer cells [25]. Juglone is a naphthoquinone. Plumbagin [12] and shikonin [26, 27] are among
the best investigated naphthoquinones that have cancer cell inhibitory activities. . Plumbagin and
shikonin inhibit cancer viability and proliferation via generation of ROS suggesting that
naphthoquinones in general cause cancer cell apoptosis by generating more ROS in the cells. .
Mitochondria-mediated apoptosis involves regulation by pro-apoptotic and anti-apoptotic
BCl-2 family of proteins [28]. Bax and Bad are among the best characterized pro-apoptotic
proteins and Bcl-2, Bcl-xl and Mc11 are among the best characterized anti-apoptotic proteins.
When apoptotic signals like excess generation of ROS are triggered in cells, the Bax proteins
translocate to mitochondrial outer-membrane and creates permeability transition pore, which
allows the release of pro-apoptotic proteins such as cytochrome C that are responsible for the
activation of caspases. Bcl-2 acts as an anti-apoptotic protein by heterodimerization with Bax and
not permitting Bax to create pores in the membranes of mitochondria [28]. Therefore, the ratio of
Bcl-2 to Bax is very important in determining whether proliferative or apoptotic events occur in a
cell [29]. The Bcl-2/Bax ratio was lower in juglone-treated MIA Paca-2 cells than the control cells
suggesting an increase in cell apoptosis (Figure 3.3.). Xu et al. showed that Bcl-2/Bax ratio was
lower in juglone-treated leukemia cells than the control [7].
Caspases play an essential role in the induction of apoptosis. Caspases remain as inactive
zymogens in cells and only undergo proteolytic activation when undergoing apoptosis. Caspase-3
are the effector caspases and involved in initiation of apoptosis [30]. Our data suggest that when
MIA Paca-2 cells were treated with juglone, caspase-3 was activated in a dose-dependent manner
(Figure 3.2., C). Confirmation of activated caspase-3 is also provided with the cleavage of PARP
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which are substrates of caspase-3 and undergo cleavage upon caspase activation (Figure 3.2, A)
[14]. Taken together, these results confirm that juglone-induced apoptosis is mediated by
activation of caspase as well as reduction of Bcl-2/Bax ratio, the latter is associated with
mitochondrial apoptotic pathway.
Many types of cancers; breast, ovarian, gastric, colorectal including pancreatic cancer are
known to express HER-2 receptors, a transmembrane receptor tyrosine kinase of the epidermal
growth factor family [31]. One of the other abnormalities that is seen in cases of pancreatic cancer
is the overexpression of epidermal growth-factor receptors. In particular pancreatic cancer MIA
Paca-2 cells overexpress HER-2 [32]. Expression of HER-2 occurs in 7-61% of pancreatic cancer
cases [33, 34]. Overexpression of HER-2 is responsible for various oncogenic processes like
cancer cell survival, proliferation, invasion and angiogenesis via activation of various signal
transduction pathways such as Ras/Raf/MAPK and PI3k/Akt/mTOR [35]. Peptidyl prolyl
isomerase (Pin1) enzyme activity is very high in various cancers, is induced by oncogenes such as
Ras and Neu, and is associated with regulation of HER-2 expression and cellular transformation
[36]. Pin 1 catalyzes phosphorylation and amplification of EGF pathways and interacts with MEK
to induce HER-2 expression which suggests that Pin1 plays an important role in overexpression
of HER-2 receptors in tumors [36]. Importantly, juglone has been reported to be a known inhibitor
of Pin1 activity [37] and therefore is considered as an important molecule to investigate for its
activity against cancer.
Targeting HER-2/neu receptors in pancreatic cancer cells has been described as one of the
treatment approaches [33] as HER-2 overexpression is found to be responsible for chemoresistance and low survival of cancer patients [31, 38]. Tyrosine kinase inhibitors like Trastuzumab
(Herceptin) were developed to treat cancers that overexpress HER-2 [39]. Anti-tumor effect of
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Trastuzumab has also been reported in HER-2 overexpressing pancreatic cancer xenograft [40].
However, the full length HER-2 (p185) is known to undergo proteolytic cleavage, which generates
a 95 kDa HER-2 fragment [41]. The p95 truncated portion of HER-2 (p95HER-2) is shown to
possess higher kinase activity causing increase in intracellular signaling and its presence has been
linked to lymph node metastasis in breast cancer [42]. Trastuzumab acts against HER-2 by binding
to the extracellular domain and one of the major events that is accountable for the resistance to
Trastuzumab is the shedding or cleavage of HER-2 receptors [43]. Presence of truncated p95HER2 fragments in tumors is associated with chemo resistance to HER-2 targeted therapies. It is
suggested that treatment approaches have to be modified in such cases [43]. The importance of
p95HER-2 fragments in HER2-targeted therapies have been studied in tumor samples from breast
cancer patients; 51.4% of patients positively responded to Trastuzumab and the response was
lowered to only 11.1% in cases where tumor samples were p95HER-2 positive [44]. In our study,
occurrence of basal level of full length and truncated forms of HER-2 was seen in MIA Paca-2
cells and treatment of juglone was significantly able to block the expression of both in a dose
dependent manner (Figure 3.4.). Therapies that have been developed by targeting this specific
receptor have been documented as an efficient anti-cancer approach. Ability of juglone to inhibit
the expression of truncated and full length HER-2 makes it a very attractive therapeutic agent for
treating p95HER-2-positive tumors, and this study is first of a kind to report inhibition of truncated
p95HER-2 fragments in pancreatic cancer cells.
Yun et al. demonstrated using in vitro and in vivo experiments that juglone at 50 µM in
combination with 50 µM of Trastuzumab inhibited the expression of HER-2 receptors and
enhanced the effectiveness of Trastuzumab in both breast BT474 cancer cells and tumor xenograft
model in BALB/C mice [45]. Similarly, plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone), a
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quinoid compound isolated from root of Plumabago zeylanica [46] which is very closely related
molecule to juglone has been recognized to downregulate the expression of HER-2 and p-Akt in
lung cancer H460 cells [47]. However, plumbagin was not able to downregulate ERK signaling.
In our study, juglone was shown to inhibit the expression of HER-2 as well as its 95kDa protein
fragment as shown in Figure 3.4. Juglone (5µM) in 12-O-tetradecanoylphorbol-13-acetate (TPA)induced mouse skin epidermal JB6 CI41 cells downregulated the activities of PI3K, an important
event required for cancer cell metabolism and growth [48]. In the same study, it was also
demonstrated that juglone could inhibit TPA-induced phosphorylation of Akt, which remains in
agreement with our findings. Herein our study has reported successful findings on juglone-induced
inhibition of phosphorylation of ERK, which was not observed in other studies carried out using
juglone in TPA-induced mouse epidermal cells [48]. The results of this investigation suggest that
juglone inhibits the expression of HER-2 receptors by inhibiting phosphorylation of ERK in
pancreatic cancer MIA Paca-2 cells.
Cyclooxygenases are a group of enzymes responsible for conversion of essential fatty
acids, arachidonic acid to prostaglandins and are found in two different isoforms; COX-1 and -2.
The level of COX-2 is very low in normal cells and is found to be prominent in pancreatic cancer
tumors. The level of COX-2 in pancreatic cancer was reported to be sixty times higher than in their
normal counterpart and was detected in 90% of pancreatic cancer [49]. Inhibition of cell intrinsic
COX-2 expression has been linked to delay in pancreatic cancer development and progression
[50]. COX-2 is shown to upregulate tumor aggressiveness by inducing expression of anti-apoptotic
protein Bcl-2 and activating Akt. Phosphorylation of Akt and activation of COX-2 are interrelated
[50]. Drugs that target both COX-2 and Akt are required to develop an effective chemotherapy in
order to limit tumor growth and overcome chemo-resistance. Therefore, to investigate whether
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downregulation of p-Akt also results in inhibition of COX-2, western blot analysis of MIA Paca2 cancer cells treated with juglone was done. Celecoxib, a COX-2 inhibitor has shown promising
results in decreasing tumor weight and inhibiting metastasis in mice bearing pancreatic cancer
xenograft [51]. COX-2 inhibitors execute their role by releasing cytochrome C, activation of
caspases, and cleavage of PARP [52]. The upregulation of COX-2 in pancreatic cancer and its role
in tumor growth provides an important rationale to target COX-2 pathway. Our results indicate
that the level of COX-2 molecules was significantly suppressed in juglone-treated cells in a dose
dependent manner at concentration as low as 1 µM. Like other COX-2 inhibitors [53], in this study
juglone was found to inhibit COX-2 (Figure 3.7) along with Bcl-2 (Figure 3.3) and Akt (Figure
3.5.). Similar inhibition of COX-2 activity using juglone was previously been determined in TPAinduced COX-2 activation in mouse epidermal cells [48].
Increased aerobic glycolysis is another abnormal phenomena observed in cancer cells. This
process was first described by Otto Warburg in 1926 and therefore is also known as the “Warburg
effect”. The Warburg effect has been recognized as the seventh hallmark of cancer [54, 55].
Normal cells usually depend upon mitochondrial oxidative phosphorylation for generation of
energy, and only undergo aerobic glycolysis in absence of oxygen whereas cancer cells mostly
rely on aerobic glycolysis even in presence or absence of oxygen [56]. Generation of ATP via
aerobic glycolysis (2 ATP/glucose) is more significantly energy inefficient than oxidative
phosphorylation (36 ATP/glucose), therefore utilization of glucose by cancer cells is a lot higher
in order to produce enough ATPs required for their vigorous metabolism. Dependency of cancer
cells on glycolytic pathways for energy can be exploited to design therapies that can target the key
biomolecules involved in the pathway [57].
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The first step in glycolysis is the formation of glucose-6-phosphate from glucose, which is
irreversibly catalyzed by hexokinase enzyme [58]. Hexokinases are predominantly expressed in
many tumor cells and function in catabolism of glucose in rapidly proliferating tumor cells. In this
study, we report for the first time that juglone inhibited glycolysis via downregulation of
hexokinase in human pancreatic cancer cell. Hexokinase has also been linked to the mitochondrial
apoptotic related BCl-2 family proteins [59]. Downregulation of hexokinase also leads to
upregulation of mitochondrial pro-apoptotic protein Bax [60] which was observed in this study
using juglone on MIA Paca-2 cells. Other known glycolytic inhibitors such as iodoacetate and 3bromopyruvate are reported to decrease pancreatic cancer cell survival and proliferation [61].
Shikonin, a quinone based compound similar to juglone was reported to inhibit hexokinase in
glioblastoma cells [62]. In the same study, shikonin in combination with a commercial glycolytic
inhibitor showed promising results in inhibiting proliferation and angiogenesis in in vitro and in
vivo experiments [62]. These studies support the importance of inhibiting glycolytic pathways in
cancer cells by naphthoquinone derivatives as a promising therapeutic strategy.
Our results of juglone-induced inhibition of hexokinase (Figure 3.8) are comparable to the
study performed using curcumin in HT29 colon cancer cells [63]. Curcumin was shown to
significantly inhibit hexokinase activity but had no effect on other glycolytic enzymes. Other
natural flavonoids that are documented with anti-glycolytic effect include oroxylin A, a molecule
derived from root of Scutellaria baicalensis used in traditional Chinese medicine [64]. Oroxylin
A indirectly inhibited peptidyl-prolyl cis/trans isomerase (Pin1) activity in breast cancer cells
which eventually caused inhibition of hexokinase and glycolytic activity. Oroxylin A, like juglone
is a known Pin1 inhibitor [65]. Taken together, our results suggest that juglone could modulate
the glycolytic activity in pancreatic MIA Paca-2 cancer cells by inhibiting hexokinase activity.
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3.5. Conclusion
Juglone possess various biological activities against pancreatic cancer MIA Paca-2 cells.
Findings that are listed in this chapter indicate that juglone-induced cytotoxicity is based on
generation of reactive oxygen species, upregulation of pro-apoptotic molecules, downregulation
of anti-apoptotic molecules, and activation of caspase-3, followed by cleavage of PARP which
eventually causes DNA damage and subsequent cell death. Other depicted molecular events are
altered expression of oncogenic markers, downregulation of activation of Akt, COX-2, Erk,
tyrosine receptors like HER-2, and inhibition of glycolytic enzyme. These findings provide a
rationale for further in vivo and pre-clinical evaluation of juglone on pancreatic cancer.
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CHAPTER 4. ANTI-ANGIOGENIC AND ANTI-METASTATIC ACTIVITIES OF
JUGLONE AGAINST PANCREATIC CANCER CELLS
4.1. Introduction
Pancreatic cancer accounts for 3% of all cancers in the United States and still is the fourth
leading cause of cancer related deaths in the US. The estimated number of new cases in the year
2015 was 48,960 and number of death was 40,560 [1]. The five- year survival rate for patients
with pancreatic cancer is 6% with median survival time of 3-6 months [2]. Surgical resection,
chemotherapy or radiotherapy are the current treatments for early stage pancreatic cancer; however
there is no curative option for advanced pancreatic cancer, which is usually metastatic in nature.
Better treatment approaches are needed to target pancreatic cancer metastasis.
The metastatic ability of malignant tumors plays an important role in tumor progression.
Cancer metastasis is accountable for more than 90% of cancer related deaths ([3-5]. The principal
sites of metastasis for pancreatic cancer cells are liver and lungs [6]. Metastasis involves a series
of four sequential steps: detachment, migration, invasion and adhesion described as the “invasionmetastasis cascade” [7, 8]. The adhesion and detachment ability of cells, interaction with other
cells and with the extracellular matrix defines the extent of invasiveness of tumor cells.
Angiogenesis, or the formation of new blood vessels, is an essential process of tumor metastasis
[9].
Tumor cells produce growth factors, like vascular endothelial growth factor (VEGF),
which regulates angiogenesis and stimulates blood vessel formation. The newly formed blood
vessels are a primary route for tumor cells to escape the primary site and enter into circulation
[10]. Several anti-angiogenic therapeutic approaches have been developed. Many natural products,
phytochemicals and dietary agents such as gallic acid, rhein, luteolin, and quercetin have been
extensively studied for their anti-angiogenic potential as a therapy against cancer [11].
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Juglone (5-hydroxy-1,4-naphthoquinone) is a natural quinone based compound and is a
derivative of 1, 4-naphthoquinone. Juglone is isolated from plants of the Juglandaceae family and
commonly found in black walnut, English walnut, butternut and others [12]. Juglone has been
reported to be a component of ancient medicine for ringworm, fungal, bacterial and viral infections
[13], and only limited studies have been conducted to understand the anti-tumor properties of
juglone [12, 14, 15].
No study has yet demonstrated the anti-metastatic potential of juglone in pancreatic cancer
cells. Therefore, the present experiments were designed to study the inhibitory activities of juglone
against the migration and invasion of human pancreatic cancer MIA Paca-2 cells in vitro.
4.2. Materials and Methods
4.2.1. Reagents
Juglone was purchased from Sigma-Aldrich (St. Louis, MO). Primary and secondary
antibodies for vascular endothelial growth factor (VEGF, #sc-7269) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). β-actin ((#4967), Akt ( #2966) and p-Akt (#2531s) were
purchased from Cell Signaling Technology (Danvers, MA).
4.2.2. Cell Culture
Human Umbilical Vein Endothelial Cells (HUVEC) and pancreatic cancer MIA Paca-2
cells were purchased from American Type Cell Culture. Cells were cultured in a humidified
incubator containing 5% CO2 at 37oC. HUVEC were maintained in Medium 200 (Invitrogen)
supplemented with Low Serum Growth Supplement (LSGS kit, Invitrogen). MIA Paca-2 cells
were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10 % fetal bovine serum,
penicillin and streptomycin and both cell lines were sub-cultured after reaching 70-80%
confluency.
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4.2.3. In-vitro Endothelial Cell Tube Formation Assay
This assay was performed as suggested by the manufacturer using the in vitro angiogenesis
assay kit from MilliporeTM. Briefly, 50 μl of matrigel was added to the wells of a 96-well plate at
4oC and allowed to polymerize at 37oC for at least 1 h. Human umbilical vein endothelial cells
(HUVEC) were then seeded at a density of 1x103 cells per well on the surface of the matrix. Cells
were then treated with juglone at concentrations ranging from 100 nm to 10 μM.
In a different set, HUVEC were also treated with conditioned media collected from MIA
Paca-2 cells treated with juglone. Cells were then allowed to incubate at 37 oC for at least 6 h and
tube formation was analyzed and photographed using a Leitz phase-contrast inverted microscope
at 10X magnification. Length of the capillaries were measured by using Image-Pro software
(Media Cybernetics, Inc, Warrendale, PA).
4.2.4. Wound Healing Migration Assay
MIA Paca-2 cells were plated in 96-well plates overnight to achieve a confluent cell layer.
A linear wound was created with micropipette tips and cell layers were washed twice with serum
free media to remove the floating cells. Cells were then treated with juglone (0, 1, 5 or 10 μM).
The effect of juglone on tumor cell migration was observed after 24 h incubation. Each well of the
plate was photographed at the same site at 0 h and 24 h and compared. The width of the wound at
0h and 24 h was measured using Image-Pro Software. Results are expressed as the ratio of wound
width at 0 and 24 h after treatment [16].
4.2.5. Transwell Migration Assay
Transwell Migration is also referred to as Boyden chamber assay. MIA Paca-2 cells at 70%
confluence were treated with juglone (0, 1, 5 or 10 µM)) for 6 h and after treatment viable cells
were harvested with 0.25% trypsin EDTA (Invitrogen, CA) and plated at a density of 5x10 4 MIA
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Paca-2 cells in 200 μl serum-free growth media per insert in the apical chamber of Transwell with
8 μM pore size (Corning). The basal chamber was filled with 500 μl of medium with 20% FBS as
a chemoattractant. After 72 h of incubation, media from the apical and basal chambers of transwell
were removed and non-migrated cells in the apical chamber were scraped off by moist cotton swab.
Cells in the undersurface of the transwell inserts were washed with phosphate buffer saline
(PBS) and then fixed with 70% ethanol for 15 min at room temperature. Fixed cells were then
stained with 0.25% crystal violet (CV). After 30 min of incubation with CV, excess dye was
removed and the inserts were washed in running water. Images of stained cells were captured with
Leitz phase-contrast inverted microscope. Retained CV in cells were dissolved with 33 % acetic
acid and optical density was read at 595 nm (Benchmark Plus, BioRad, Hercules, CA).
4.2.6. Matrigel Invasion Assay
Matrigel invasion assay is used to evaluate chemotaxis and the ability of tumor cells to
invade the extracellular matix [16, 17]. The matrigel invasion assay is similar to the transwell
migration assay however, the difference in the set-up is that the inserts in the transwell insert are
first coated with ECM matrix (matrigel). Matrigel (BD Biosciences) was thawed overnight at 4oC,
diluted with serum-free media in the ratio of 1:1 and 50 μl of matrigel was added to each transwell
insert. Transwell inserts with matrigel were placed in the incubator at 37oC for at least 1h to form
a thin layer gel. The rest of the protocol was similar to the one described in the migration assay.
4.2.7. Expression of HIF-1α and VEGF
MIA Paca-2 cells were plated in a black 96 well plate (R&D Systems, Minneapolis, MN)
at a cell density of 1x104 cells per well. After allowing cells to attach overnight, cells were treated
with juglone (1, 5 or 10 µM) for 6h. After required incubation, media were removed and cells were
washed with PBS. Immediately, cells were fixed with 4% formaldehyde for 15 min. After 15 min,
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cells were washed with PBS and endogenous peroxidase activity of cells was blocked by
incubation with 30% hydrogen peroxide for 15 min. Cells were then incubated with blocking
buffer for 1 h, washed with PBS at least 3 times and incubated overnight with HIF-1α antibody.
VEGF was analyzed in cell lysates by Western Blot. In brief, cells were plated at a cell
density 2.5 x105cells/well in a six well plate. After seeding overnight, cells were treated with
juglone for 6 h. After 6 h, media was removed and cells washed with phosphate buffer saline.
Whole cell lysate was prepared by using cell lysis buffer from Cell Signaling Technology. Protein
concentrations of the samples were determined using the BCA assay.
Fifty µg of protein was loaded in SDS polyacrylamide gel; 4-12 % Bis-Tris (Invitrogen,
Carlsbad, CA). Prepared samples were separated by gel electrophoresis and transferred to
polyvinylidene difluoride (PVDF) membranes (Invitrogen, Carlsbad, CA). Membranes were
blocked with 5% BSA in TBS containing 0.05% Tween 20 (TBS-Tween) for 1h. The PVDF
membranes were then incubated with primary antibody in TBS-Tween containing 5% BSA
overnight at 4oC with gentle agitation.
Visualization of the bound primary antibody was done by probing the membrane with
horseradish peroxidase–conjugated secondary antibodies and exposure to chemiluminescent
substrate (Thermo Fisher Scientific). Chemiluminescence was recorded by BioRad Imaging
system. For quantification, densitometric analysis of the bands were done by Quantity One 1-D
analysis software (BioRad, CA).
4.2.8. Statistical Analysis
All the experiments were conducted in triplicates. Results are expressed as means ± SD of
experiments. Analysis of variance (ANOVA) will be conducted to examine the differences
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between treatments followed by Tukey’s analysis using SAS. A P-value of <0.05 was considered
to be statistically significant. Means with different letters indicate significantly different.
4.3. Results
4.3.1. Juglone Inhibits in-vitro Tube Forming Ability of Endothelial Cells
The results of this experiment showed dose-dependent inhibition of endothelial cell
alignment (Figures 4.1. and 4.2.). When endothelial cells were treated with juglone there was a
dose dependent inhibition. Juglone was effective in reducing the length of the tubes in vitro at a
concentration as low as 250 nM (Figure 4.1.) and at concentration of 5 and 10 µM, the network
was completely disrupted and was not readable (NR).
Highly organized, extensively aligned capillary-like structures were formed in untreated
HUVEC. Similarly, highly organized and extensively aligned capillary-like structures were
formed when HUVEC were treated with conditioned media from MIA Paca-2 cells (Figure 4.2.).
4.3.2. Juglone Suppresses Pancreatic MIA Paca-2 Cells Migration
The wound scratch assay was performed for analyzing the effect of juglone in inhibiting
migration. The width of the wound was measured after 24 h of treatment and the ratio of wound
size at 0 h and 24 h was calculated (Figure 4.3., A). All the treatments with juglone resulted in
inhibition of closure of wounds.
In untreated cells, the ratio was 1.3. In cells treated with 1, 5 and 10 μM juglone, the ratio
dropped to 1.24, 1.11, and 0.91, respectively. These ratios are presented in terms of percentage of
untreated cells in Figure 4.3, B. A similar pattern was observed in the transwell chamber migration
assay where juglone treatment significantly decreased the number of migrated cells at 5 μM and
10 μM (Figure 4.4.).
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4.3.3. Juglone Inhibits Pancreatic Cancer MIA Paca-2 Cell Invasion
The Boyden Chamber assay was used to evaluate the effect of juglone on MIA Paca-2 cell
invasion. To rule out the cytotoxic effect of juglone on migration and invasion, cells were treated
with juglone (1, 5 or 10 µM) for 6h and only viable cells were collected and utilized for both
migration and invasion assay.
Results in Figure 4.5. show that juglone dose-dependently inhibited the invading potential
of MIA Paca-2 cells. When MIA Paca-2 cells were treated with 1 μM juglone, 34.8% of the
pancreatic cancer cells maintained their ability to invade the matrigel. When MIA Paca-2 cells
were treated with 5 μM juglone, 28.9% of the pancreatic cancer cells were able to invade the
matrigel. And when MIA Paca-2 pancreatic cancer cells were treated with 10 μM, only 0.3% of
MIA Paca-2 pancreatic cancer cells maintained their ability to invade the matrigel.
4.3.4. Juglone Inhibits Expression of Proteins Associated with Cell Migration and Invasion in vitro
The level of HIF-1α in MIA Paca-2 cells after treatment of juglone was measured by cell
based ELISA and is reported in Figure 4.6. The results of western blot on analysis of p-Akt and
VEGF are also shown in Figures 4.7 and 4.8. Results indicate that juglone dose-dependently
inhibited the levels of VEGF, p-Akt and HIF-1α (Figures 4.6-4.8).
4.4. Discussion
Several studies suggest that juglone possesses numerous anti-cancer properties. The effect
of juglone as an anti-cancer agent against ovarian cancer cells was reported [18]. Zhang et al. [19]
demonstrated the inhibitory activities of juglone against cervical cancer cells. However, there are
no reports on the effect of juglone in pancreatic cancer cells. This study investigated the inhibitory
activity of juglone against the migration and invasion of human pancreatic cancer MIA Paca-2
cells in vitro.
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Figure 4.1. Effect of juglone on HUVEC tube formation. HUVEC were plated on top of
polymerized matrigel, incubated with various concentrations of juglone and tube formation was
observed after 6h of incubation (A). The length of capillaries formed was measured using
ImagePro software and represented (B). At concentrations 5 and 10 µM the lengths were not
readable (NR).
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Figure 4.2. Effect of juglone on HUVEC tube formation using conditioned media (CM) from
MIA Paca-2 cells. Results were compared to HUVEC grown in regular media (RM). HUVEC
were plated on top of polymerized matrigel, incubated with various concentrations of juglone
containing conditioned media (CM) from MIA Paca-2 cells and tube formation was observed
after 6h of incubation (A). The length of capillaries formed was measured using ImagePro
software and represented (B).
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Figure 4.3. Effect of juglone on wound closure. A. Confluent layer of MIA Paca-2 cells were
scratched with micropipette tips (upper panel A) and cells with wounds were incubated with
varying concentrations (1-10 μM) of juglone for 24 h. Photographs of the wound were taken at 0
h (upper panel A) and at 24 h (lower panel B) of incubation. Quantitative representation of
wound closure was measured using Image Pro software and ratio of width of the wound before
and after treatment is presented (B).
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Transwell Cell Migration Assay
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Figure 4.4. Effect of juglone on the migration of MIA Paca-2 cells. Cells were treated with
various concentrations of juglone for 6h. After treatment, cells were harvested and live cells were
plated (5x104) on the upper chamber of transwell inserts and allowed to migrate for 48h. Invaded
cells on the undersurface of the inserts were stained with crystal violet and photographs were
captured with a phase contrast microscope (A). Retained crystal violet by migrated cells were
dissolved in acetic acid and optical density was measured at 595 nm and expressed as percentage
of control (B).
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Figure 4.5. Effect of juglone on the invasion ability of MIA Paca-2 cells. Cells were treated with
various concentrations of juglone for 6h and after treatment, cells were harvested and plated
(1x105) on the upper chamber of transwell inserts with matrigel layer and allowed to invade for
48h. Invaded cells on the undersurface of the inserts were stained with crystal violet and
photographs were captured with a phase contrast microscope.
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Figure 4.6. Expression of HIF-1α in MIA Paca-2 cells treated with juglone as measured by a cell
based ELISA assay.
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Figure 4.7. Western Blot analysis of VEGF expression in MIA Paca-2 cells. Cells were treated
with various concentrations of juglone (1-10 μM) for 6h and cell lysates were collected. Western
blot was performed with 30 μg of protein/lane (A). Expression of VEGF was quantified using
Quantity One software and reported as percentage of control (B).
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Figure 4.8. Western Blot analysis of Akt and p-Akt expression in MIA Paca-2 cells. Cells were
treated with juglone (1-5 μM) for 6h and cell lysate were collected. Western blot was performed
with 70 μg of protein/lane (A). Quantification of p-Akt/Akt ratio was done using Quantity One
software and reported as percentage of control (B).
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Juglone at 1μM significantly inhibited the migration and invasion capabilities of pancreatic
cancer MIA Paca-2 cells. Cancer cells grow rapidly and are efficient in migrating and closing the
artificial scratch wound. Decrease in the ratio of the size of the wound with time and dose of
juglone suggests that cancer cell migration can be significantly reduced with juglone treatment.
To understand the molecular mechanism behind angiogenesis, studying the expression of
angiogenic markers such as Vascular Endothelial Growth Factor (VEGF) is important. VEGF
overexpression is regulated by Hypoxia inducible factor (HIF-1α) [20, 21] and is associated with
significant metastasis, angiogenesis and poor prognosis of PC [22]. Angiogenesis inhibitors are
beneficial in reducing tumor growth and metastasis. Many naphthoquinone derivatives like
Vitamin K2 [23] have been reported to act as inhibitors of angiogenesis. In this study, the antiangiogenesis mechanism of juglone, a naphthoquinone derivative was studied in functions of
HUVEC and results demonstrate that juglone strongly inhibits the formation of capillary-like
network as shown in Figure 4.1. Our results agree with the findings from a study where 1, 4naphthoquinone was used as a drug of interest and inhibited HUVEC tube formation at a similar
concentration as juglone [24]. The tube formation assay was also performed using conditioned
media from MIA Paca-2 cells and results are presented in Figure 4.2. The tube formation in
HUVEC was higher when media from cancer cells was used when compared to regular media used
in culturing HUVEC (Figure 4.2.), which might be due to the increased level of growth factors
released by cancer cells in culture. Even in this set of experiments, juglone containing conditioned
media inhibited tube formation. These results of tube formation assays taken together suggest
juglone as a strong anti-angiogenesis agent, which can be beneficial in treating cancer.
Akt plays a central role in regulating angiogenesis as it transmits signals received from
cytokines and growth factors to upregulate HIF-1α and VEGF expression in cancer cells. There
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exists an autocrine loop between Akt and VEGF expression and Akt activation is a requirement
for HIF-1α and VEGF expression [25]. Various natural compounds e.g. resveratrol from grapes,
capsaicin from pepper have shown inhibitory effect on HIF-1α and VEGF by inhibiting the Akt
pathway [26]. Juglone at 20 μM in combination with ascorbate (1mM) was recently shown to
inhibit p-Akt in breast cancer MCF7 cells [27]. Our results indicate that juglone by itself is very
effective in inhibiting p-Akt at 5μM in pancreatic cancer MIA Paca-2 cells (Figure 4.8.).
The transcription factor hypoxia inducible factor - 1α is very closely related with the
regulation of numerous genes associated with angiogenesis [28], erythropoiesis, glycolysis, iron
metabolism, and cell survival [29]. Besides, the level of oxygen tension there are other oxygen
independent factors like nitric oxide [30], cytokines, serum, insulin, and insulin-like growth factors
[31] that can enhance the activity of HIF-1α. Overexpression of HIF-1α in human tumors is
connected to metabolic pathways that might lead to the activation of tumor angiogenesis, invasion,
and metastasis [32, 33]. In this present study, our results demonstrated that juglone significantly
decreased the level of HIF-1α compared to the untreated control (Figure 4.6.). Previous studies
with anthraquinones such as emodin or rhein [34] have shown its efficacy in inhibiting migration
and invasion of cancer cells with down regulation of associated proteins like HIF-1α and VEGF
[35], which is in agreement with our data (Figures 4.6. and 4.7.).
One of the downstream signaling molecule of HIF-1α is VEGF, which is considered as an
important factor for regulating angiogenesis and is related to growth and metastasis of pancreatic
adenocarcinoma [21, 36]. VEGF is highly expressed in physiological cases like wound healing
and embryonic development and in pathological cases like cancer. A recent study has
demonstrated that juglone inhibited tumor proliferation, angiogenesis and migration of breast
cancer MCF7 cells via downregulation of VEGF and cyclin E proteins [37]. In our study, juglone
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significantly inhibited VEGF expression in MIA Paca-2 cells (Figure 4.7.). Juglone inhibited
pancreatic cancer cells wound closure, migration and invasion (Figures 4.3.-4.5.) and one of the
underlying molecular mechanisms may involve reduced expression of VEGF.
4.5. Conclusion
In summary, juglone appears to have the ability with cell-based models to inhibit
angiogenesis and metastasis behavior of pancreatic cancer MIA Paca-2 cells. While we have
demonstrated that juglone appears to be a promising anti-cancer agent and inhibits metastasis and
angiogenesis of pancreatic cancer cells in vitro, these results further warrant future preclinical
animal studies and, if successful, clinical trials need to be followed to confirm the efficacy of
juglone in in-vivo models for the treatment of pancreatic cancer.
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CHAPTER 5. SUMMARY AND CONCLUSIONS
Many studies have been carried out to understand the biological function of juglone in
various types of cancer. The purpose of this dissertation was to evaluate the antitumor effect of
naturally occurring quinone juglone in human pancreatic cancer cell model and have revealed its
molecular targets. Evaluation on effect of juglone as an anti-angiogenic/anti-metastatic agent was
also performed.
We have found out that juglone exerted cytotoxic effect and inhibited proliferation of
pancreatic cancer cells in vitro. Morphological changes associated with apoptosis upon treatment
of MIA Paca-2 cells with juglone was recorded. Significant inhibition in the clonogenic potential
of cancer cells treated with juglone was also observed. Induction of apoptosis was further
confirmed by occurrence of externalization of phosphatidylserine molecule, which was recorded
by Annexin V staining and analysis of various molecular markers of apoptosis. The activity of
caspases were found to be upregulated followed by cleavage of PARP in cells with exposure to
juglone. Anti-apoptotic molecules like Bcl-2 were downregulated and there was an upregulation
of pro-apoptotic molecules like Bax.
Most quinones exert its cytotoxic effect with their general redox cycling mechanism and
production of reactive oxygen species. Similarly, our data showed that juglone also induced
production of ROS. Furthermore, it was found that like other quinones, juglone targeted DNA of
cells and pattern of DNA fragmentation was observed in cells treated with juglone. Other cellular
events that were affected by juglone included inhibition of epidermal growth factor receptor (HER2), phosphorylation of ERK, inhibition of COX-2, and reduced activity of the glycolytic enzyme
hexokinase.
Anti-angiogenic and anti-metastatic actions of juglone were also investigated. Numerous
quinone moiety containing drugs have been proven effective in inhibiting angiogenesis making
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quinones an attractive agent for cancer therapy. Our findings suggest that juglone possess strong
potential to inhibit angiogenesis and metastasis. The ability of endothelial cells to form capillary
like network was disrupted with influence of juglone. The anti-angiogenic effect of juglone has
been supported by the findings that juglone inhibited the central pro-angiogenic growth factor
VEGF along with its regulators HIF-1α and Akt. Further, the effect of juglone on the ability of
cancer cells to migrate and invade was conducted by using cell migration and invasion assays. It
was found that pancreatic cancer cells treated with juglone significantly lost its ability to migrate
and invade. These results indicate that juglone can inhibit the metastatic spreading of pancreatic
tumor cells.
Based on our data, it can be extrapolated that juglone possess anti-cancer properties against
pancreatic cancer and this compound can be further utilized in the process of drug discovery. The
limitation of this research project is that all the studies were performed in cell culture models. It is
unknown how the results will be translated in mouse models and human samples. Therefore future
studies using juglone needs to be carried out in animal models in order to validate our findings and
also to understand the absorption, distribution, metabolism and excretion (ADME) profile of
juglone.
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